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Macrophages are innate immune cells that participate in host defense to invading 
pathogens.  They are powerful producers of cytokines and inflammatory mediators due to 
their efficient recognition of pathogen associated molecular patterns (PAMPs) via toll 
like receptors (TLRs).  We and others have shown that the activation response to PAMPs 
is transient.  In the present work, we demonstrate that stimulated macrophages produce 
adenosine and prostaglandin E2, which function as regulators of the macrophage 
activation response.  Macrophages also upregulate receptors for these regulators to 
terminate inflammation and promote wound healing.   We performed high throughput 
RNA sequencing to characterize the transcriptomes of human monocyte-derived 
macrophages in response to stimulation with LPS + Adenosine or LPS + PGE2.  These 
cells exhibited a decrease in inflammatory transcripts and an increase in transcripts 
associated with cell growth and repair when compared to cells stimulated in the absence 
of these regulators.   
Macrophages can be generated from precursor cells in response to two different 
growth factors; M-CSF (macrophage colony stimulating factor) and GM-CSF 
(granulocyte-macrophage colony stimulating factor). M-CSF is expressed constitutively 
in a variety of tissues, while GM-CSF is expressed primarily in the lung, but can be 
	
induced in other tissues under inflammatory conditions. We demonstrate that human 
macrophages differentiated in M-CSF readily adopt an anti-inflammatory, growth 
promoting phenotype in response to LPS + Adenosine or LPS + PGE2, while 
macrophages differentiated in GM-CSF do not.  This observation suggests that M-CSF 
derived human macrophages may be better able to alter their activation state in response 
to surrounding signals in order to maintain homeostasis.   GM-CSF derived macrophages, 
in contrast, may undergo a more prominent activation response that is associated with 
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1 Introduction 
Parts of this chapter are adapted from published works:  
Hamidzadeh, K., S.M. Christensen, E. Dalby, P. Chandrasekaran, and D.M. Mosser. 
2017. Macrophages and the Recovery from Acute and Chronic Inflammation. Annu. 
Rev. Physiol. 79:567–592. doi:10.1146/annurev-physiol-022516-034348. 
Hamidzadeh, K., and D.M. Mosser. 2016. Purinergic Signaling to Terminate TLR 
Responses in Macrophages. Front. Immunol. 7:74. doi:10.3389/fimmu.2016.00074. 
1.1 Macrophages and Innate Immunity 
Macrophages reside in almost all tissues of the body and engage in inflammatory 
processes in order to protect the host from invading pathogens and to fight infection.  
They are part of the innate immune system, which is the host’s first line of defense once 
an immunogen has bypassed external barriers such as the skin.  Macrophages are efficient 
phagocytes and are able to rapidly clear debris, dead cells, and microbes at the site of 
infection.  In addition to phagocytosis, macrophages release important inflammatory 
mediators including cytokines in order to initiate systemic immune responses.  These 
inflammatory macrophages are a vital component of host defense.   However, the 
transition to an anti-inflammatory state is crucial during the resolution of infection in 
order to prevent damage to host tissue.  The failure to resolve inflammation can result in 
autoimmunity. 
Macrophages originate from two different sources: the embryonic yolk sac, and 
hematopoietic stem cells in the bone marrow1.  During inflammation, tissue macrophages 
can be derived from circulating blood monocytes.  These cells migrate to the tissue, or 
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sites of inflammation, where they encounter signals such as macrophage-colony 
stimulating factor (M-CSF) and granulocyte macrophage-colony stimulating factor (GM-
CSF) that promote their differentiation into macrophages.  It has been demonstrated that 
during chronic infection, macrophages from embryonic origin largely disappear, and are 
replaced with macrophages of hematopoietic origin in the lung, liver, and peritoneum 
among other tissues2,3.  Macrophages residing in close proximity to a variety of signals 
exhibit dramatically different phenotypes.  
1.2 Macrophage polarization 
Macrophages represent a heterogeneous population of immune cells.  Because 
they are present in so many tissues, they are exposed to a wide variety of 
microenvironments and must be able to respond to a wide range of stimuli.  Macrophages 
express the family of surface receptors known as Toll-like receptors (TLRs), which are 
able to recognize pathogen associated molecular patterns (PAMPs).  These are conserved 
patterns present on pathogens that the cells have evolved to recognize efficiently to 
mount an inflammatory immune response. In addition to PAMP signals, macrophages 
also recognize small molecules in their surroundings that allow them to alter their 
phenotype.  This is termed macrophage “plasticity” and it is important that macrophage 
phenotypes can be reversed.  Due to the plasticity of these cells, macrophages with an 
infinite number of diverse phenotypes may exist4.  However, it is generally accepted that 
3 main populations of macrophages may represent the polar extremes of macrophage 
phenotypes.    These include classically activated (M1), alternatively activated (M2), and 
“regulatory” macrophages.  While these 3 groups have been initially defined in the 
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mouse5, it is proposed that macrophage activation falls along a spectrum as they exist 
within diverse environments within the human host. 
M1 Macrophages 
M1 macrophages are defined by stimulation with interferon gamma (IFNγ) + 
lipopolysaccharide (LPS).  Early on in infection the type II interferon, IFNγ, is produced 
by innate and adaptive immune cells.  Macrophages exposed to IFNγ are primed for 
secretion of large amounts of inflammatory cytokines, and reactive oxygen and nitrogen 
species6.  This secretion is typically triggered by a second stimulus.  Classically activated 
macrophages receive a secondary signal through TNF receptor or TLR stimulation.  
Stimulation of TLRs results in the activation of NFκB transcription factors, which induce 
the transcription of pro-inflammatory cytokines such as IL-12 and TNF, and many 
cytokines and mediators through interferon response elements.  Our lab has contributed 
to the body of knowledge surrounding classically activated mouse macrophages by 
demonstrating that IFNγ primed bone marrow-derived macrophages (BMDMs) do not 
downregulate their own activation state7.  This occurs due to the failure to upregulate the 
A2br receptor, which renders these macrophages insensitive to the endogenous anti-
inflammatory effects of adenosine. 
M2 Macrophages 
M2 macrophages are typically induced in response to IL-4 or IL-13.  These 
macrophages produce precursors important for collagen production.  These same 
precursors may lead to tissue fibrosis and Th2 pathology.   While IL-4 alone does not 
induce cytokine production in these macrophages, it does promote the induction of 
arginase (Arg1)6.  IL-4 receptor stimulation also results in the activation of STAT68.  
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Alternatively activated macrophages are considered to be more susceptible to microbial 
infection and intracellular pathogens and this is thought to be through the metabolism of 
L-arginine to polyamines9.  In this way, arginase induction diverts arginine away from
NO production and provides microorganisms with necessary nutrients for survival.  
Surprisingly, M2 or alternatively activated macrophages have not sufficiently been 
characterized in humans.  Preliminary, unpublished, transcriptomic data from our lab 
indicates that IL-4 treatment of monocyte-derived macrophages has a more limited effect 
on their phenotype, with little overlap with the effects of IL-4 treatment of mouse 
macrophages.  
Regulatory Macrophages 
Regulatory macrophages (R-Mϕ) were first defined in our laboratory in mouse 
bone marrow derived macrophages10,11.  They require a combination of an inflammatory 
signal, such as TLR stimulation and a secondary signal, which can include immune 
complexes, adenosine or prostaglandin E25,12.  The hallmark of regulatory macrophages is 
the reciprocal change of IL-10 and IL-12 cytokine production.  In mouse, R-Mϕ produce 
high levels of IL-10 compared to LPS stimulation alone.  IL-10 is an anti-inflammatory 
cytokine, which can act to suppress macrophage activation and it is critical for the 
resolution of inflammation.  R-Mϕ stimulated with adenosine and PGE2 produce 
decreased amounts of IL-12 despite the inflammatory TLR signal.  IL-12 is involved in 
the initiation of cell-mediated immune responses.  Our lab has identified a number of 
other highly upregulated genes in regulatory macrophages, including growth and 
angiogenic factors, and we were able to demonstrate that these macrophages are distinct 
from classically and alternatively activated macrophages.  From RNA sequencing data, it 
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is hypothesized that regulatory macrophages are not only involved in decreasing 
inflammation but also involved in promoting homeostasis.  
1.3 Toll like receptors: 
The innate immune system is our first line of defense against foreign antigens.  It 
is critical that the innate immune response acts quickly and efficiently in order to destroy 
invading pathogens.  Through the evolutionary process, mammalian innate immune cells 
became equipped with a number of cell surface and intracellular receptors, known as 
Toll-like receptors (TLRs), that are able to recognize highly conserved and repetitive 
sequences known as pathogen associated molecular patterns (PAMPs)13.  In this way, 
TLRs can rapidly trigger an immune response to different pathogens. 
TLR signaling 
TLRs are type I transmembrane glycoproteins.  The extracellular portion of TLRs 
is composed of between 16 and 28 leucine rich repeats that contain conserved amino acid 
motifs14.  TLR signaling originates with dimerization of the receptor and subsequent 
recruitment of adaptor proteins to its intracellular TIR domain15.  There are five adaptors 
that can initiate TLR signaling: MyD88, MAL, TRIF, TRAM, and SARM16.  The adaptor 
MyD88 is critical for the production of inflammatory cytokines by all TLRs. MyD88 
recruits IRAK-4 to the receptors, which then activates IRAK-1 and IRAK217.  Activated 
IRAKs associate with TRAF6, and this complex can then activate two pathways18. The 
first is the MAPK pathway leading to AP-1 transcription factor activation.  The second is 
the phosphorylation of IκB kinase, which dissociates from the IKK complex in order to 
activate the NF-κB transcription factor.  These transcription factors lead to the production 
of many inflammatory genes.   
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Lipopolysaccharide and TLR4 
 One of the most widely used tools to activate macrophages is lipopolysaccharide 
(LPS), a TLR ligand.  LPS is a glycolipid present in the outer membrane of gram-
negative bacteria including E. coli.  The structure of LPS consists of a hydrophobic lipid 
A component, hydrophilic core of polysaccharides, and O-antigen19.  Trace amounts of 
LPS in certain tissues, such as blood, can lead to a fatal disease called sepsis due to 
uncontrollable amounts of inflammation and this toxicity is primarily due to the lipid A 
component20.  LPS is recognized by TLR4, which forms a heterodimer with myeloid 
differentiation factor 2 (MD-2) that aids in LPS binding21,22.  Two additional proteins are 
also required for LPS recognition, LPS binding protein (LBP) and CD1423.  LBP 
facilitates the association of LPS with CD1423.  CD14 is expressed on myeloid cells and 
binds to LPS, subsequently presenting it to the TLR4/MD-2 complex24.  CD14 is also 
required for endocytosis of TLR4, which is part of the signal transduction process25. 
TLR4 and its interaction with LPS is one of the most studied and well-characterized 
processes in innate immunity. 
1.4 Adenosine in the Immune System: 
 
Adenosine is a purine nucleoside circulating at low levels in the blood and in 
tissue.  Adenosine concentrations surrounding cells can increase via nucleoside transport 
proteins in the cell membrane, or via ATP catabolism (Illustration 1).  ATP and 
adenosine can be released in local environments by platelets, dead and dying cells, 
tumors, and from endothelial cells, among other sources.  It is proposed that all immune 
cells can contribute to adenosine concentrations due to the fact that ATP is produced by 
Illustration 1. ATP catabolism at the macrophage surface.  ATP is converted to 
adenosine via the action of two ecto-enzymes, CD39 and CD73.  Adenosine signals 
through the A2a and A2b receptors which are coupled to Gαs proteins.  This leads to an 
increase in intracellular cAMP levels.
Figure from:
Hamidzadeh, K., and D.M. Mosser. 2016. Purinergic Signaling to Terminate TLR 
Responses in Macrophages. Front. Immunol. 7:74. doi:10.3389/fimmu.2016.00074.
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glycolysis and immune cells express the ecto-enzymes required to convert this ATP to 
adenosine. 
ATP Release and Hydrolysis 
ATP release from resting macrophages is low, but ATP release is significantly 
increased following TLR activation26.  Some of the cytosolic ATP generated following 
TLR stimulation is released into the extracellular milieu through pannexin-1 channels.  
This ATP is catabolized by macrophages in a coordinated two-step process. ATP is first 
hydrolyzed to AMP by the surface ecto-enzyme CD39 (E-NTPDase1) in a Ca2+ and Mg2+ 
dependent process27.   Next, AMP is rapidly converted to adenosine by CD73 
(Ecto5’NTase)28.  These two enzymes and their expression level on the macrophage 
surface can greatly affect the concentration of adenosine in the extracellular environment 
directly adjacent to the cell.   
Adenosine Receptor Signaling 
Macrophages respond to adenosine via signaling through the P1 class of seven 
transmembrane G-protein coupled receptors (GPCR), which includes: A1R, A2aR, 
A2bR, and A3R29. The A1 and A3 receptors are coupled to the Gi family of proteins, 
which act to decrease cAMP levels.  A2a receptors are Gαs-coupled receptors which act 
to increase intracellular cAMP, and they are high affinity for adenosine30,31.  Similarly, 
A2b receptors can signal through Gαs or Gq proteins, also leading to increased cAMP, but 
these receptors are low affinity for adenosine30,32.  In combination with TLR stimulation, 
adenosine drives the transition from a pro-inflammatory to a regulatory macrophage4.  
Adenosine is immuno-suppressive in mouse macrophages as it leads to increased IL-10 
release and decreased TNF and IL-12 release26.   High-throughput RNA-sequencing data 
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from our lab indicated that macrophages stimulated with LPS in combination with 
adenosine upregulated 501 transcripts and downregulated 610 transcripts relative to LPS 
exposure alone5.  Furthermore a number of the upregulated transcripts were involved in 
cell growth, while many of the downregulated transcripts were involved in 
inflammation33. 
While signaling through GPCRs controls the levels of intracellular cAMP, the 
role of the cAMP/PKA pathway in terms of inflammatory cytokine inhibition by 
adenosine receptor signaling is not fully understood.  Some researchers have proposed 
that the inhibition of macrophage TNF production by adenosine is due to a cAMP/PKA-
independent pathway, and is rather a pathway dependent on phosphatases34.  However, 
others have shown that cAMP/PKA levels are linked to TNF production in an inverse 
manner35.  It has also been shown that the A2bR interacts with and inhibits NFκB, and 
that A2bR knockout macrophages produce less IL-10 and more IL-12 and TNF36.  Thus, 
adenosine may regulate macrophage phenotypes by mechanisms that have not yet been 
fully elucidated.    
Adenosine in disease 
Adenosine receptors have been associated with a variety of diseases.  These 
receptors are expressed in many tissues including the brain, heart, spleen, muscle and 
lung37,38.  This ubiquitous pattern of expression is one of the obstacles of developing 
therapeutics that are able to specifically target the receptors.  Studies have been done that 
reveal a role for A2aR and A2bR in diabetes due to the fact that they are involved in the 
regulation of glucose as a result of increased cAMP39–41.  There is potential for A2ar 
agonists to be anti-inflammatory in ischemia reperfusion injury42. A2aR and A2bR have 
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both been implicated in reducing foam cell formation, which is a feature of 
atherosclerosis43,44.  However, it has been demonstrated that knocking out the A2ar has a 
protective outcome in a mouse model of hypercholesterolemia largely due to the fact that 
macrophages in these mice are pro-inflammatory and therefore reduce atherosclerotic 
lesions45.  Furthermore, adenosine receptors contribute to wound healing and modulate 
cytokine production by macrophages of patients with chronic obstructive pulmonary 
disease29,46. 
1.5 Prostaglandin in the immune system: 
Prostaglandins are bioactive lipids present in many tissues that are implicated in 
processes including proliferation, angiogenesis, and inflammation.  They are part of the 
prostanoid family of lipids, which are synthesized step-wise from fatty acids. There are 
numerous prostaglandins that can be synthesized, including PGI2, PGD2, and PGF2, but 
the most studied and widely acting prostaglandin is PGE2.  PGE2 is typically seen as a 
perpetuator of inflammation, which is why it is the target of non-steroidal anti-
inflammatory drugs (NSAIDs).  This is true for many cell types including T and B cells.  
However, the opposite is true for macrophages, as PGE2 promotes the production of anti-
inflammatory molecules and the shutting off of cytokine production. 
PGE2 synthesis and secretion  
First, phospholipases hydrolyze membrane phospholipids, releasing arachidonic 
acid47.  Next, arachidonic acid is oxidized into PGG2 and reduced to PGH2 by the 
cyclooxygenase enzymes COX-1 and COX-247.  These two enzymes are highly 
upregulated throughout the immune system in response to pro-inflammatory signals48,49.  
Lastly, PGH2 is converted into PGE2 via three synthases: mPGES-1, mPGES-2, and 
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cPGES49.  PGE2 levels are regulated by both its synthesis and by its degradation.  15-
PGDH and 13-PGR are catabolic enzymes that rapidly remove PGE2 from the cellular 
environment50. 
PGE2 receptor signaling 
Macrophages respond to PGE2 via four transmembrane G-protein coupled 
receptors: EP1-4.  EP2 and EP4 are coupled to Gαs proteins, which stimulate intracellular 
cAMP production51. In combination with TLR stimulation, PGE2 inhibits IL-12 and TNF 
and partially decreases IL-6 production by macrophages52–54.  At the same time, PGE2 
enhances IL-10 release from mouse macrophages in a PKA-dependent manner55.  PGE2 
inhibits inflammasome activation in macrophages via signaling through the EP4 receptor, 
dampening the production of IL-1β56.  Additionally, IL-17 production is increased in the 
presence of PGE2 therefore promoting M2 macrophage microenvironments57. Our lab 
previously showed that mouse macrophages stimulated with LPS and PGE2 exhibit an 
immuno-regulatory phenotype58.   
PGE2 and the immune response 
PGE2 helps to regulate the activation of many cells of the innate immune 
system59. The involvement of PGE2 in acute inflammation has been well-documented60 
but, in contrast, PGE2 has also been demonstrated to also play a significant role in 
immunosuppression60,61.  Inflammation in the lung in response to allergens and 
pollutants, as well as colonic inflammation, is dampened by PGE2 through the EP4 
receptor signaling on macrophages62,63. PGE2 also downregulates MHC class II 
expression on dendritic in lymphoid organs in order to decrease antigen presentation64.  It 
has been demonstrated that PGE2 inhibits the phagocytosis of bacterial pathogens and 
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bacterial killing by alveolar macrophages in a dose-dependent manner65,66.   Along with 
this, many bacteria and intracellular parasites, including L. donovani, have developed 
mechanisms to stimulate PGE2 production by macrophages in order to suppress 
inflammation and promote survival inside the host59,67,68. 
Cyclooxygenase (COX) inhibitors are commonly used NSAID drugs that inhibit 
inflammatory responses.  However, it has been shown that chronic inhibition of the COX 
enzymes in macrophages drives them towards a pro-inflammatory phenotype, partly due 
to lower synthesis of PGE269.  Furthermore, it has been proposed that these classic 
inhibitors of prostaglandin synthesis may act to prolong chronic inflammation when 
taken during the resolving phase70.  Macrophages are well-known producers of PGE271.  
Exposure of macrophages to LPS increases arachidonic acid metabolism, leading to 
greater PGE2 secretion72.  Since macrophages synthesize endogenous PGE2, we recognize 
the profound effects of this molecule on the regulation of macrophage activation. 
1.6 Interferons and innate immunity: 
Type I Interferon 
Interferons (IFNs) are cytokines that are best known for their involvement in the 
immune response to viral pathogens.  However, IFNs also affect the response to 
microbial pathogens, the stimulation of antigen presentation, cell proliferation and 
apoptosis73.  Type I IFNs include IFNα and IFNβ and signal through the heterodimeric 
IFNα receptor (IFNAR).  Signaling through IFNAR activates Janus kinase 1 (JAK1) and 
tyrosine kinase 2 (TYK2), followed by activation of signal transducer and activator of 
transcription (STAT) transcription factors, STAT1 and STAT2 as well as IFN regulatory 
factor 9 (IRF9)74,75. Type I IFNs can be produced by many cells and in macrophages they 
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can be produced following stimulation of TLR4, TLR3, TLR7 and TLR918.  The effects 
of Type I IFN in response to bacterial infection are complicated and not fully understood.  
Often times they can contribute to host resistance to bacteria but sometimes they can 
promote bacterial survival via suppression of the innate immune response76.  In mouse 
models of sepsis, Type I IFN deficiency led to a reduction in endotoxin lethality despite 
no change in inflammatory cytokine levels77.  Type I IFNs also have contradicting roles 
in autoimmune disorders.  Patients with systemic lupus erythematosus (SLE) have 
increased type I interferon in circulation that is thought to promote disease78.  On the 
other hand, IFNβ administration is an effective treatment for multiple sclerosis79.  The 
activity of Type I IFNs appears to be highly context dependent. 
Type II Interferon 
The Type II IFN family consists solely of IFNγ, which signals through a 
heterodimeric IFNγ receptor to activate JAK1 and JAK2, which subsequently activate 
STAT180.  Further downstream, IRF1 is strongly induced by IFNγ which promotes Th1 
responses73,81.  IFNγ is highly efficient at priming macrophages for enhanced bacterial 
killing and inflammation82.  Its ability to enhance bacterial killing is largely mediated 
through nitric oxide and superoxide production83,84.  IFNγ is used as effective treatment 
for patients with chronic granulomatous disease, in which phagocytes are defective in 
superoxide and hydrogen peroxide production85.  Priming also acts in coordination with 
TLR signaling to stabilize mRNAs that encode inflammatory genes leading to more 
efficiency in both transcription and translation of these proteins86,87.  Type II IFN is 
mainly produced by natural killer (NK) cells and Th1 cells in response to infection88.   
While it is highly effective at stimulating innate immune cells to control pathogens, it can 
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have negative consequences for the host.  For example, IFNγ contributes to the 
pathogenesis of rheumatoid arthritis and SLE89,90.  Overall, IFNγ is effective at 
potentiating inflammatory immune responses. 
1.7 Colony-stimulating factors: 
M-CSF and GM-CSF are both colony-stimulating factors that are important in
myeloid cell differentiation and immune modulation.  Many studies have addressed the 
role of these two growth factors in terms of cell survival, as they prolong the life of 
macrophages and are regulators of hematopoiesis.  A few gene expression studies have 
been done comparing macrophages differentiated in each growth factor in both mouse 
and human33,91–93. However, extensive research has not been done on the inflammatory 
response of both M-CSF and GM-CSF macrophage populations and their sensitivity to 
endogenous mediators.   
M-CSF
M-CSF signals through the C-FMS receptor or CSF-1R.  This receptor is a single
pass type I membrane protein and has a tyrosine kinase domain94.  Upon binding of M-
CSF, receptors dimerize.  Downstream of this receptor is PI3K, Src family kinases, Ras, 
ERK1/2, Akt, and PLCγ2 signaling94–96.  SHIP2 tyrosine phosphorylation following M-
CSF stimulation leads to reduced Akt activation and inhibition of NFκB gene 
transcription independently of a functional SH2 domain, unlike SHIP197.  Macrophages 
have been shown to regulate the levels of M-CSF in circulation by CSF-1R mediated 
endocytosis98. 
M-CSF is produced ubiquitously by many cells types including endothelial cells,
lymphocytes, fibroblasts and monocytes99.   CSF1R is critical for the maintenance of 
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monocyte and macrophage populations.  Mice lacking CSF1R are deficient in several 
tissue macrophage populations including Kupffer cells, microglia and skin 
macrophages100.   The addition of recombinant human M-CSF in mice resulted in a 
significant increase in blood monocytes in circulation and an expansion of resident 
macrophage populations101.  Increased levels of M-CSF have been reported in numerous 
diseases including arthritis, pulmonary fibrosis, inflammatory bowel disease, and 
cancer102.  A number of monoclonal antibodies and small molecules targeting the CSF-
1R have been in clinical trials for targeting solid tumors102. 
GM-CSF 
GM-CSF signals via the βc receptor Type I cytokine receptor family, similarly to 
IL-3 and IL-5.  A ternary complex between the βc receptor, the GM-CSF receptor 
specific alpha chain and the GM-CSF molecule is required for signaling103.  Downstream 
of the GM-CSF receptor complex is JAK2/STAT5 activation, MAPK, and PI3 
kinase/Akt pathway activation104,105.  GM-CSF also activates NFκB by interaction of the 
alpha chain of the GM-CSF receptor and IκB kinase106. Further downstream, GM-CSF 
activates IRF5 transcription factor, which shapes macrophage polarization107.  It has 
recently been shown to also activate IRF4 in order to drive the CCL17. 
GM-CSF, like M-CSF, can also be produced by endothelial cells, epithelial cells, 
and fibroblasts that are activated, but is mainly produced by TH17 T cells and innate 
lymphoid cells in response to infection or trauma99.  The inflammatory cytokine, IL-1 
appears to be particularly important in the induction of GM-CSF from a number of cell 
types108–111. There are a multitude of diseases in which the circulating levels of GM-CSF 
are increased including encephalomyelitis, rheumatoid arthritis, systemic 
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inflammation112, and even allergic responses113.  Multiple clinical trials for monoclonal 
antibodies to GM-CSF have been undertaken in the context of rheumatoid arthritis, 
asthma and multiple sclerosis102.  The main tissue in which GM-CSF is constitutively 
expressed is the lung.  Humans with a point mutation in the common beta chain of the 
GM-CSF receptor develop a condition called pulmonary alveolar proteinosis (PAP)114.  
Mice lacking GM-CSF develop lung abnormalities and also have symptoms mirroring 
PAP115.  Additionally, these GM-CSF deficient mice are more susceptible to local 
infections, in the lung particularly115.  For example, neutralization of GM-CSF in mice 
led to a reduction in protective immunity to histoplasma infection, indicating that this 
cytokine plays a role in host defense116. 
1.8 Macrophage activation during disease or injury 
Sepsis 
Macrophages are critical drivers of inflammation due to their potent cytokine 
producing capabilities.  In the case of sepsis, this high level of cytokine production, 
known as a “cytokine storm”, by macrophages in the early phases of infection is what 
leads to a high mortality rate for the host.  Sepsis is a serious condition that affects over 
30 million people per year, and results in over 5 million deaths.  The blockade of 
inflammatory cytokines such as TNF and IL-1 have proven to be inefficacious in the 
reversal of sepsis.  However, the anti-inflammatory cytokine IL-10 contributes 
significantly to the progression of the disease.  Cecal ligation and puncture model (CLP) 
in IL-10 knockout mice was associated with 15-fold higher serum levels of TNF, but 
treatment with recombinant IL-10 led to improved survival and a longer therapeutic 
window for rescue surgery117.  Regulatory macrophages are partly defined by their ability 
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to secrete increased amounts of IL-10.  A previous graduate student in our lab 
demonstrated in mice, that macrophages stimulated with LPS + Adenosine and LPS + 
PGE2 had a protective effect on mouse survival when injected into the peritoneum of the 
mice in an endotoxemia model118.   Additionally, earlier work in our lab demonstrated 
that FcγR ligation promotes IL-10 production in mice, leading to protection in sepsis 
models11.   Therefore, multiple methods of generating these regulatory macrophages can 
have a potentially therapeutic effect in sepsis.  
Tumor associated macrophages 
Macrophages are one of the main immune cells residing in the tumor 
microenvironment.  These macrophages are termed tumor associated macrophages 
(TAMs) and generally are not activated against the tumor. The production of pro-
inflammatory cytokines by macrophages in the tumor environment is critical for the 
activation of cytotoxic T cell responses119.  A few treatment strategies such as checkpoint 
inhibitors and CAR T cell therapies targeting tumor antigens have proven successful in 
many cancer patients.  However, it has been demonstrated that in those patients in which 
these immunotherapies are unsuccessful, there can be an abundance of tumor associated 
myeloid cell infiltrates, including macrophages120.  These macrophages display an 
immunosuppressive, and pro-angiogenic phenotype.  Tumors secrete immunosuppressive 
molecules, including both adenosine and PGE2, which we believe shapes the macrophage 
phenotype to one that is anti-inflammatory and angiogenic in order to support the tumor’s 
growth121,122.  Therefore, methods of reversing or preventing this macrophage phenotype 
could prove beneficial in cancer patients.  
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Intracellular Parasitic Infections 
Macrophages are host to numerous parasitic and bacterial pathogens.  These 
pathogens include Leishmania, Mycobacteria, Toxoplasma, and Trypanosoma, among 
others123.  These pathogens reside intracellularly and have evolved numerous 
mechanisms to evade the intense macrophage anti-pathogen response.  The anti-pathogen 
response includes the formation of reactive nitrogen and oxygen species, protease 
activation, programmed cell death, and cytokine production124.  The phenotype of 
macrophages largely affects the survival of these pathogens within them.  For example, 
many studies have demonstrated that L. major have decreased cell proliferation and 
increased death in macrophages that produce nitric oxide and super oxide in mice125–128.  
A number of molecules can stimulate macrophages to produce these oxygen radicals 
including zymosan, LPS and IFNγ.   GM-CSF also changes the macrophage phenotype 
leading to poor L. major and L. tropicana survival129,130.  Additionally, GM-CSF has 
been shown to increase hydrogen peroxide release by mouse peritoneal macrophages and 
GM-CSF cultured microglia restricted the intracellular multiplication of T. gondii via the 
synthesis of reactive nitrogen intermediates131,132.  GM-CSF also leads to greater control 
of T. cruzi by inhibiting its replication via increased IL-12, NO and IFNγ 
production133,134. Conversely, M. tuberculosis seem to have increased survival in GM-
CSF macrophages compared to M-CSF macrophages135.  One study showed that adding 
M-CSF to restore homeostatic levels in the lungs of M. tuberculosis infected mice, led to
greater activation of the adaptive immune response to the pathogen and led to decreased 
survival136.  Overall, manipulation of the macrophage phenotype has clear consequences 
for the survival of intracellular pathogens. 
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Wound Healing 
Macrophages play a critical role in the response to injury in muscle, skeleton, skin 
and other organs.  While macrophages initially mount an inflammatory immune response 
following injury, they also are active in the return to homeostasis137.  An early study in 
mice found that the depletion of macrophages in the wound sites led to delayed 
debridement and also slowed fibroblast recruitment and proliferation affecting the wound 
closure time138. The wound healing process is largely orchestrated by the macrophage 
secretome.  The secretome includes molecules like TGFβ, VEGF and EGF, which have 
been shown to be essential for angiogenesis. One early study indicated that recombinant 
human M-CSF accelerated wound healing in non-ischemic wounds in rabbits by 
significantly increasing the levels of TGFβ 139.  The timing of the conversion of 
inflammatory, TNF producing macrophages to growth promoting, TGFβ secreting 
macrophages is particularly important in muscle regeneration140,141.  Other molecules 
secreted by macrophages, such as anti-inflammatory cytokines IL-10, IL-4 and IL-13 
along with lipid mediators like lipoxins and resolvins can contribute to the initiation of 
tissue repair.  In muscle, infiltrating blood monocytes that differentiate into macrophages 
convert to pro-regenerative macrophages that promote the growth of new myofibers once 
phagocytosis of debris is complete142. Macrophages also indirectly contribute to wound 
healing by recruiting other cell types such as fibroblasts, mesenchymal cells and 
mesoangioblasts143.  Subsequently, macrophages promote the proliferation of these cells 
at the wound site in order to instruct the tissue repair mechanism and initiate 
angiogenesis144.  If macrophages do not function properly during wound healing, this can 
lead to fibrosis.    
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1.9 Scope and Limitations 
The research in this dissertation was performed on human monocyte-derived 
macrophages.  These cells represent a subset of macrophages in the host that develop 
once monocytes migrate into different tissues in response to inflammatory signals, and 
subsequently encounter colony-stimulating factors.  We studied these macrophages due 
to the feasibility of their collection from human blood.  Although these macrophages are 
separate in origin from yolk sac or fetal liver-derived tissue macrophages, we believe that 
all macrophages exhibit plasticity and can respond to molecules in their 
microenvironment in order to alter their phenotype. 
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2 Materials and Methods 
2.1 Mouse BMDM preparation 
Bone marrow hematopoietic stem cells were flushed from the femurs of 6-8 week old 
C57/bl6J mice (Cat# 000664, Jackson Laboratory, Bar Harbor, ME) in saline containing 
1% penicillin/streptomycin145.  Cells were plated on petri dishes in DMEM/F-12 + 
Glutamax media (Cat# 10565018, Life Technologies, Grand Island, NY) containing 10% 
heat-inactivated fetal bovine serum (Cat# S11550, Atlanta Biologicals, Flowery Branch, 
GA) supplemented with 20% conditioned media obtained from the culture of the L-929 
mouse fibroblast cell line (Cat# ATCC).  New media was added on day 4.  On day 7, 
differentiated macrophages were removed from petri dishes using Cell stripper (Corning).  
Other strains of mouse macrophages were also used including A2br-/-146, A2ar-/- and 
STAT1-/- mice (Cat#s 010685, 012606, Jackson Laboratory).  
2.2 Mouse BMDM stimulation 
Mouse macrophages were stimulated with the following reagents: 10 ng/mL ultra pure 
LPS from Escherichia coli K12, IFNγ 10000 U/mL, IFNβ 10000 U/mL, and IFNλ 10000 
U/mL.  They were also stimulated with various TLR-ligands (Cat# tlrl-kit1mw, 
Invivogen). 
2.3 Human macrophage differentiation 
Whole blood was isolated from healthy donors under University of Maryland, IRB 
approved protocols.   Human monocytes were isolated via density gradient centrifugation 
followed by negative isolation using immunomagnetic beads (Cat# 130-096-537, 
Miltenyi Biotec, San Diego, CA).  Monocytes were cultured for 7 days in X-VIVO 15 
serum-free media (Cat# 04-744Q, Lonza, Walkersville, MD) containing 1% penicillin-
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streptomycin, 1% L-glutamine (Cat# 25-005-CI, Gibco, Gaithersburg, MD), and 
supplemented with either 30 ng/mL recombinant human M-CSF or 20 ng/mL 
recombinant human GM-CSF (Cat# AF-300-25, Cat# 300-03 respectively, Peprotech, 
Rocky Hill, NJ).  Media containing either growth factor was replenished on day 4 
following initial culture.  Prior to stimulation on day 7, media containing growth factor 
was replaced with X-VIVO 15 media containing 5% heat-inactivated fetal bovine serum 
(Cat # S11550, Atlanta Biologicals, Flowery Branch, GA). 
2.4 Human macrophage stimulation 
LPS stimulated macrophages were generated by the addition of 10ng/mL ultra pure LPS 
from Escherichia coli K12 (Invivogen, San Diego, CA).  LPS + Adenosine macrophages 
were generated by the addition of 10 ng/mL LPS and 50 µM adenosine (Cat# A4036, 
Sigma-Aldrich, St. Louis, MO).  LPS + PGE2 macrophages were generated by the 
addition of 10 ng/mL LPS and 50 nM PGE2 (Cat# 2296, Tocris, Bristol, UK).  
Pharmacological inhibitors, ONO AE3 208, PF 04418948, SCH 442416, were used to 
inhibit EP4, EP2 and A2aR, respectively (Cat#s 3565, 4818, 2463, Tocris).  TLR 
agonists, FSL-1, HKLM, Loxoribine, and Poly I:C were added to macrophages for 4 
hours (Cat#s tlrl-fsl, tlrl-hklm, tlrl-lox, tlrl-pic Invivogen).  Cell permeable cAMP 
analogs, 8-Bromo-cAMP, specific for PKA, and 8-pCPT-2-O-Me-cAMP-AM, specific 
for Epac, were added to stimulated macrophages for 24 hours (Cat#s 1140 and 4853, 
respectively, Tocris). 
2.5 RNA sequencing sample and library preparation 
Total RNA was isolated from macrophages using the Trizol reagent.  RNA cleanup was 
done using RNeasy Mini Kit columns (Cat# 74106, Qiagen, Hilden, Germany).  RNA 
23	
quality was determined using an Agilent 2100 bioanalyzer.  Poly(A)+-enriched cDNA 
libraries were generated using the Illumina TruSeq sample preparation kit (Cat#s 
16027084, 15027387, 1502062, Illumina, San Diego, CA) and quality of the cDNA was 
determined again with the bioanalyzer.  Paired end reads (100bp) were obtained from an 
Illumina HiSeq 1500.  Reads were aligned to the human genome 
(Homo_sapiens.GrCh38.79) obtained from the UCSC genome browser 
(http://genome.ucsc.edu) using Kallisto147.  Count tables were restricted to protein-coding 
genes (34,425) and on-expressed or weakly expressed genes (< 1 read per million in n=5 
samples) were removed prior to subsequent analyses, resulting in 12,857 genes analyzed.  
Quantile normalization and log2-transformation was done on all samples. 
2.6 RNA sequencing data assessment, visualization and differential expression 
analysis 
Limma, a Bioconductor package, was used to perform differential expression analysis.  
The voom module was used to transform the data based on observational level weights 
derived from the mean-variance relationship prior to statistical modeling.  Experimental 
batch effects were adjusted for by including experimental batch as a covariate in our 
statistical model.  Differentially expressed genes were defined as genes with a log2 fold-
change > 1 and a Benjamini-Hochberg (BH) multiple-testing adjusted p. value < 0.05.  
All components of the statistical pipeline, named cbcbSEQ, can be accessed on GitHub 
(https://github.com/kokrah/cbcbSEQ/). 
2.7 Single cell RNA-sequencing sample and library preparation  
Monocyte derived macrophages generated in M-CSF from a single donor were stimulated 
for 4 hours with nothing, LPS, LPS + Adenosine and LPS + PGE2 and processed 
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according to the 10x library preparation method.  Briefly, Gel Beads-in-emulsion 
(GEMs) were generated by combining Single Cell 3’ v3 Gel Beads, master mix 
containing cells, and partitioning oil onto Chromium Chip B.  Following GEM 
generation, the Gel Beads were dissolved and mixed with primers containing the 10x 
Barcode, a TruSeq sequencing primer, a unique molecular identifier and a poly(dT) 
sequence, in order to produce full-length, barcoded cDNA.  This barcoded cDNA was 
amplified by PCR in order to construct libraries.  The above components were included 
in a library construction kit (Cat# PN-1000075, 10x Genomics, San Francisco, CA).  
Libraries were sequenced using paired-end Illumina sequencing. 
2.8 Single Cell RNA-sequencing analysis 
The samples were sequenced and processed with cell ranger 3.0.1 at 
the Johns Hopkins Genetics Resources Core Facility. The resulting 
outputs were passed to Seurat 3.1.0, merged by sample, and filtered 
to remove cells with high mitochondrial content (> 15%) and few features 
(< 200).  The remaining data was passed through the default Seurat 
pipeline.  The analysis was done on 17306 cells, with an average of 4327 cells per 
sample.  The analysis entailed normalization, variable feature selection, data 
scaling, neighbor and cluster searches, the accompanying visualizations, and 
differential expression of markers across conditions and samples. 
2.9 ELISA 
Cytokine and growth factor levels were measure in the supernatants of 24 hour stimulated 
macrophages.  IL-12p40 and TNF were measured using paired antibody ELISA kits 
(Cat# BMS2013MST, Invitrogen, Vienna, Austria and Cat# 555212, BD Biosciences, 
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San Diego, CA).  GM-CSF, VEGF, and THBS1 were measured using DuoSet ELISA kits 
(Cat#s DY215, DY293B, DY3074, respectively, R&D, Minneapolis, MN). 
IL-6 and IL-10 were also measured using OptEIA ELISA sets (Cat#s 555220 and 
555157, respectively, BD Biosciences). 
2.10 Quantitative real-time PCR 
RNA was isolated from cells using the Trizol reagent.  cDNA was synthesized using 
Superscript VILO cDNA synthesis kit.  Relative quantitation of transcript levels was 
performed using SYBR-Green.  Samples were analyzed in a Roche Light Cycler 480.  
Expression levels were calculated using the ΔCt method relative to the geometric mean of 
GAPDH and RAB7 as internal control genes.  The primer sequences used to measure 
transcripts are listed in Table 1. 
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Table 1. Primer Sequences 


































































































NM_007413.4 5’-GACTCTTCGCCATCCCCTTT -3’ 
5’-ACAGCAATGATCCCTCTCGC-3’ 
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2.11 Measurement of PGE2 production 
Prostaglandin E2 levels in the supernatants of 24 hour LPS stimulated M-CSF and GM-
CSF macrophages were measured using a monoclonal antibody competitive ELISA kit 
(Cat # 514010, Cayman Chemical, Ann Arbor, MI). 
2.12 Measurement of ATP degradation 
M-CSF and GM-CSF macrophages were given a spike of 20 µM ATP (Cat# A6419,
Sigma-Aldrich).  Supernatants were collected at 2 hours, 1 hour, 30 minutes and 15 
minutes following this spike and ATP was measured using the ATPlite reagent (Cat# 
6016941, Perkin Elmer, Waltham, MA).  Levels of ATP were normalized to the amount 
of protein in the wells using the Pierce BCA Protein Assay Kit for protein quantification 
(Cat# 23227, ThermoScientific, Rockford, IL).  Luminescence was read in the dark-
adapted plate using a luminometer. 
2.13 HUVEC tube formation assay 
Primary human endothelial cells (HUVECs) were obtained and cultured in EGM-2 media 
(Cat# CC-3162, Lonza) on tissue culture treated plates coated with 1% gelatin from 
porcine skin (Cat# G1890, Sigma).  For the assay, HUVEC cells were distributed at a 
concentration of 40,000 cells in each well of a 48-well plate.  These wells contained 
growth factor reduced and phenol red-free Matrigel (Cat# 356231, Corning).  
Supernatants collected from M-CSF and GM-CSF macrophages that were unstimulated, 
or stimulated with LPS, LPS + Adenosine, and LPS + PGE2 for 24 hours were added to 
the HUVEC cells on the Matrigel and allowed to incubate for 24 hours.  Images of the 
HUVEC cells were captured in brightfield on an inverted Nikon ECLIPSE Ti2 
Microscope at 20x total magnification.  Images were converted to high contrast using the 
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“Find edges” function in ImageJ in order to see the cells. Tube length and number of 
nodes were assessed manually using the ImageJ software. 
2.14 Flow cytometry  
CD300E and PLAUR surface expression was measured on macrophages stimulated for 
24 hours and 8 hours, respectively, using APC conjugated antibodies (Cat# 17-3007-42 
and Cat# 17-3879-42, Invitrogen, Carlsbad, CA).  Fc block was used to reduce 
nonspecific binding (Cat# 130-059-901, Miltenyi Biotec).  Debris and doublets were 
removed using gating analysis in FlowJo version X.  Surface expression is expressed as 
median fluorescence intensity (MFI). 
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3 The effects of interferons on purinergic signaling in mouse 
macrophages 
Parts of this chapter are adapted from published work:  
Cohen HB, Ward A, Hamidzadeh K, Ravid K, Mosser DM. IFN-γ Prevents Adenosine 
Receptor (A2bR) Upregulation To Sustain the Macrophage Activation 
Response. J Immunol. 2015;195(8):3828‐3837. doi:10.4049/jimmunol.1501139 
3.1 Introduction 
It has previously been demonstrated in mouse macrophages that purinergic 
signaling dampens inflammatory responses to LPS29,148,149.  Specifically, inflammatory 
cytokines including TNF and IL-12p40 are significantly reduced in activated 
macrophages in the presence of ATP or adenosine26,150.   Purinergic signaling is thought 
to be a mechanism to control the level and duration of macrophage inflammation in the 
host.  However, there are situations in which a prolonged inflammatory response is 
desirable, such as with severe infections.  There are a number of signals that are 
associated with modulating the severity of an immune response, including interferons.  
Interferons come in different varieties, called Type I, II and III. IFN beta (IFNβ) 
and IFN alpha (IFNα) are Type I, IFN gamma (IFNγ) is Type II and IFN lambda (IFNλ) 
is Type III.   M1 macrophages, which are generated by stimulation with IFNγ + LPS 
exhibit severe inflammation151.  Our lab established a connection between interferons and 
the purinergic system in the mouse, by demonstrating that IFNγ priming of macrophages 
prevented the upregulation of the A2b receptor (A2br) following LPS stimulation7.  We 
extended this research to further explore the effects of IFNγ on adenosine signaling in 
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macrophages, and we also examined the role of Type II interferon, IFNβ, in the mouse 
macrophage response to LPS. 
3.2 Results 
Type II interferon modulation of macrophage activation.  The action of IFNγ priming 
of LPS stimulated mouse macrophages has been shown to significantly augment the 
levels of inflammatory cytokine production.  It was demonstrated in our lab that this 
heightened inflammation was due to IFNγ priming preventing the upregulation of the 
A2b receptor upon LPS stimulation7.   As part of this work, we examined the effects of 
other TLR ligands on A2BR and A2AR mRNA expression (Figure 1).  All of the TLR 
ligands tested (LPS-EK, Pam3Csk4, HKLM, Poly(I:C) LMW, Poly(I:C) HMW, ST-FLA, 
FSL-1 and ssRNA) which activate TLRs 1-9 upregulated mRNA levels for A2BR.  In all 
stimulations except ssRNA, IFNγ priming significantly downregulated expression of the 
A2BR (Figure 1A).  As for A2AR mRNA levels, there was no significant difference 
between unprimed and IFNγ primed macrophages (Figure 1B).  In order to further 
validate the effect of IFNγ priming on mouse macrophages, we looked at purinergic 
receptor expression in STAT1 -/- mouse BMDMs since IFNγ is known to signal through 
STAT1152.  The prevention of the upregulation of A2BR mRNA by IFNγ priming was 
not observed in STAT1 -/- macrophages (Figure 2A).  Additionally, STAT1 -/- 
macrophages did not significantly differ in mRNA expression of A2AR (Figure 2B). As 
expected, the lack of STAT1 abrogated the effect of IFNγ priming on TNF production 
following LPS stimulation and also allowed adenosine to function in decreasing the 
amount of TNF produced by LPS stimulated macrophages, presumably through the A2b 

















































































































Figure 1.  Adenosine receptor expression following IFNγ priming and stimulation 
with various TLR ligands.  (A) A2BR and (B) A2AR mRNA expression was measured 
by qPCR following 16 hours of IFNγ priming and 4 hours of stimulation with TLR ligands 





































































Figure 2.  Adenosine receptor expression in STAT1 knockout BMDMs.  (A) A2BR and 
(B) A2AR mRNA expression was measured in WT (black) and STAT1 KO (grey)
macrophages following 16 hours of IFNγ priming and 4 hours of LPS stimulation (n=3,
**** P-value < 0.0001 relative to WT LPS alone, #### P-value < 0.0001 between WT and
KO, error bars represent SEM).









































































































Figure 3. Cytokine levels in WT and STAT1 knockout BMDMs.  Macrophages were 
unprimed or primed for 16 hours with IFNγ followed by LPS stimulation for 8 hours at 
which point supernatants were collected and assayed for (A) TNF by ELISA (n=3, **** 
P-value < 0.0001, error bars represent SEM).  Preliminary data is shown for (B) IL-12p40
and (C) IL-10 levels assayed by ELISA (n=2, error bars represent SD).




diminished the inhibitory effect of IFNγ priming on adenosine signaling in terms of IL-
12p40 (Figure 3B) and IL-10 production (Figure 3C). Next we examined the effect of 
A2br -/- on inflammatory cytokine production and demonstrated that the downregulation 
of IL-12p40 by adenosine is mediated largely through the A2b receptor for both 
unprimed and IFNγ primed macrophages (Figure 4A). IFNγ primed macrophages 
stimulated with LPS + Adenosine also significantly differed in terms of TNF production 
in WT and A2br -/- mice (Figure 4B).  A time course experiment indicated that TNF 
levels were significantly higher in A2br -/- macrophages between 0-2 hours in the 
presence of LPS, however this difference was not sustained over time in the proceeding 
absence of LPS (Figure 4C).  
Type I interferon modulation of macrophage activation.  We wondered whether 
priming with Type I or III interferons had any effects on the purinergic pathway.  While 
IFNγ lowers mRNA expression for A2BR, IFNβ significantly increased mRNA 
expression for both A2BR (Figure 5A) and A2AR (Figure 5B) while IFNλ had no 
significant effects. Therefore, we continued to investigate the effect of IFNβ by 
examining adenosine receptor expression in IFNAR -/- mice (Figure 6).  mRNA 
expression of A2BR was higher in LPS stimulated IFNAR -/- BMDMs, but there was no 
difference in its expression in IFNβ primed WT and IFNAR-/- BMDMs (Figure 6A).  
The upregulation of A2AR mRNA expression by IFNβ priming was abolished in IFNAR 
-/- BMDMs (Figure 6B). IFNβ priming did not significantly change the levels of IL-
12p40 or TNF in WT BMDMs but increased the levels of IL-10 (Figure 7).  A2AR -/- 
BMDMs also did not significantly differ in IL-12p40 (Figure 7A) or TNF levels (Figure 






























































































Figure 4.  Cytokine levels in WT and A2B receptor knockout BMDMs.  Macrophages 
were unprimed or primed for 16 hours with IFNγ followed by LPS stimulation for 8 hours 
at which point supernatants were collected and assayed for (A) IL-12p40 and (B) TNF 
(n=3, * P-value < 0.05, ** P-value < 0.01, **** P-value < 0.0001, error bars represent 
SEM).  (C) Unprimed and IFNg primed macrophages were stimulated with LPS for 2 
hours followed by a wash.  Supernatants were collected at subsequent incubation 




























































Figure 5.  Adenosine receptor expression following priming with Type I, II and III 
IFNs.  mRNA expression of (A) A2BR and (B) A2AR was measured by RT-PCR following 
16 hours of priming with IFNγ , IFNβ, and IFNλ and subsequent stimulation for 4 hours 
with LPS (n=3, *** P-value < 0.001, **** P-value < 0.0001, error bars represent SEM).
A. B.
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Figure 6.  Adenosine receptor expession in IFNAR knockout BMDMs.  (A) A2BR and 
(B) A2AR mRNA expression was measured in WT (black) and IFNAR KO (hatched) 
macrophages following 16 hours of priming with IFNβ and 4 hours of LPS stimulation 










































































































































Figure 7.  Cytokine levels in WT and A2A receptor knockout BMDMs.  Macrophages 
were unprimed or primed for 16 hours with IFNγ or IFNβ followed by LPS, and LPS + Ado 
stimulation for 8 hours at which point supernatants were collected and assayed for (A) 




levels of these inflammatory cytokines relative to WT. In contrast, A2AR -/- BMDMs 
produced significantly lower levels of IL-10 following LPS and LPS + Adenosine 
stimulation in unprimed and IFNβ primed macrophages (Figure 7C).  Based on our 
results we concluded that priming with Type I and Type II interferons had different 
effects on the purinergic pathway in mouse macrophages. 
3.4 Discussion 
It is widely accepted that IFNγ treatment of macrophages renders them hyper-
inflammatory.  We demonstrated that this is partly due to the prevention of the 
upregulation of the A2B receptor and that this mechanism is universal for a number of 
pathogenic components that activate different TLR ligands in macrophages7.  We also 
demonstrated that the adenosine A2A receptor is not implicated in the IFNγ primed 
macrophage response.  We verified that the effects of IFNγ on A2B receptor expression 
and TNF production were mediated through the STAT1 signaling pathway as its effects 
were diminished in STAT1 knockout macrophages.  This was no surprise since IFNγ is 
known to signal through STAT1, so it should not be able to function if STAT1 is not 
present.  We demonstrated using knockout macrophages that the A2b receptor is critical 
for the immunosuppressive effects of adenosine on IL-12p40 and TNF production by 
macrophages, but that its effects are not sustained in the absence of inflammatory 
stimulus.   
In the literature, there are conflicting reports of the effects of IFNβ treatment on 
inflammation, including cytokine production76.  We observed that IFNβ increased 
transcription of both the A2BR and A2AR in macrophages, which suggests greater 
susceptibility to a spontaneous reversion to homeostasis.  This is in contrast to the IFNγ 
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downregulation of the A2B receptor, which we believe indicates that IFNβ instructs a 
milder and more controlled inflammatory response in macrophages.  Studies in IFNAR 
knockout macrophages indicated that the upregulation of A2A receptor expression was 
mediated through IFNβ and not IFNα.  However, A2B receptor expression was 
significantly higher in LPS stimulated IFNAR knockout macrophages compared to WT, 
at levels roughly equal to the level induced by IFNβ priming.  This suggested that IFNα 
may play a role in suppressing A2BR expression in WT cells, as this IFN also signals 
through the IFNAR receptor, and that perhaps IFNβ may oppose this effect.  The A2a 
receptor contributed to the production of increased IL-10 in IFNβ primed macrophages 
and their sensitivity to adenosine, as knockout macrophages produced lower levels of IL-
10 compared to wild type.   However, the A2a knockout macrophages did not produce 
notably different levels of TNF or IL-12p40.  Altogether, the data in this chapter 
implicates a role for adenosine and its receptors in the potentiation of inflammation by 
IFNγ and IFNβ in mouse macrophages.   
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4 Characterization of the transcriptome of human M-CSF derived 
macrophages stimulated with LPS + Adenosine and LPS + PGE2
4.1 Introduction 
The study of human monocyte derived macrophages is critical, considering the 
importance of these cells in a number of organs.  Monocytes infiltrate tissues and 
differentiate into macrophages following exposure to a constitutively expressed growth 
factor, M-CSF.  They do so in response to infection, or to replenish the native populations 
of tissue macrophages that may have become depleted.  It has been shown that monocyte 
derived macrophages are particularly important in the intestine, skin, and peritoneum as 
well as in disturbances such as atherosclerosis, muscle injury and inflammation153.  
In this research, we attempt to describe the phenotype of human monocyte 
derived macrophages stimulated by TLR ligands, such as LPS in the presence of 
adenosine (LPS + Adenosine) or prostaglandin E2 (LPS + PGE2), using RNA 
sequencing.  We believe that our samples and stimulation conditions mimic physiological 
environments that macrophages can potentially encounter in the body.  For example, the 
tumor microenvironment contains high levels of purinergic signaling molecules as well 
as PGE2.  These molecules are also produced during inflammatory immune responses by 
macrophages and other cell types.   We use RNA sequencing because it gives us a 
snapshot of the entire transcriptome at our chosen timepoints.  This can allow us to 
characterize the nature and function of macrophages under different physiological 
contexts. 
4.2 Results  
RNA-sequencing analysis.  RNA-seq was performed on unstimulated, LPS stimulated, 
LPS + Adenosine and LPS + PGE2 stimulated macrophages from 5 blood donors.   
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Differential expression analysis allowed us to determine the effects of adenosine and 
PGE2 on LPS stimulation (Figure 8).  Our analysis revealed that adenosine and PGE2
have similar effects on the stimulated macrophage transcriptome.  4 of the 10 most highly 
upregulated genes and 5 of the 10 most downregulated genes in LPS + Adenosine (Figure 
8A, starred) and LPS + PGE2 (Figure 8B, starred) versus LPS alone were shared. Venn 
diagrams of the number of significant differentially expressed genes further highlight the 
degree of similarity between adenosine and PGE2 stimulation relative to LPS stimulation 
alone (Figure 9A).  101 of the 259 upregulated genes and 91 of the 294 downregulated 
genes were shared by LPS + Adenosine and LPS + PGE2 stimulation. For comparison, 
LPS stimulation alone versus control leads to 1350 significantly differentially expressed 
genes (data not shown).  This highlights the fact that the transcriptomic changes made by 
the addition of adenosine and PGE2 to TLR stimulated macrophages are quite limited. 
However, at the same time, the addition of adenosine and PGE2 to TLR stimulated 
macrophages leads to a similar transcriptomic phenotype as indicated by spearman 
correlation analysis yielding a correlation coefficient of R= 0.772 (Figure 9B).  Single 
cell RNA sequencing of M-CSF macrophages from 1 donor allowed us to compare the 
trancriptomic signature of a multitude of individual cells in order to see the variable 
expression of genes within a population.  UMAP analysis was performed as a dimension 
reduction technique to cluster cells based on the variability of gene expression (Figure 
10).  LPS, LPS + PGE2 and LPS + Adenosine stimulated macrophages cluster separately 
from unstimulated cells indicating relatively homogeneous stimulation throughout the 
macrophage population.  There was some overlap between the LPS + PGE2 and LPS + 




























































Figure 8. Most highly upregulated and downregulated genes by adenosine and PGE2 
relative to LPS stimulated macrophages alone. Bulk RNA-seq was done on M-CSF 
macrphages and differential expression analysis was performed for (A) LPS + PGE2 versus 
LPS and (B) LPS + Adenosine versus LPS. The top and bottom 10 genes are listed for each 
comparison.  N=5 individuals, P-value < 0.05, log2FC > 2, error bars represent SEM.  (*) 








































Figure 9.  Degree of transcriptional similarity between LPS + Adenosine and LPS + 
PGE2 stimulated macrophages.  (A) The number of unique and shared DEGs of LPS + 
Adenosine and LPS + PGE2 relative to LPS alone are depicted as venn diagrams. (B) The 
log2FC of the DEGs of LPS + Adenosine versus LPS + PGE2 relative to LPS alone are 
depicted on a scatter plot.  Spearman correlation was performed to obtain a correlation 
coefficient (r) printed in the top left quadrant (P-value < 2.2-16).



















Figure 10.  Cluster visualisation of M-CSF macrophage single cell transcriptomes.  
Uniform manifold approximation and projection (UMAP) was used to arrange points 
(representing cells) based on their relative transcriptomes.  Single cells clustered based on 
their stimulation conditions: unstimulated, LPS, LPS + Ado and LPS + PGE2.
Figure generated with Dr. Ashton Trey Belew
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Adenosine clusters, further indicating that a number of cells in these stimulation 
conditions are transcriptionally similar.  
Pathway Analysis.  In order to explore the functional roles of macrophages stimulated 
with adenosine and PGE2, we took a closer look at the genes modulated by these 
conditions.  Of the most highly upregulated genes in common between LPS + Adenosine 
and LPS + PGE2 versus LPS alone, 10 of the top 20 genes have published growth 
promoting or anti-inflammatory roles (Figure 11A, purple).  LYPD3, or C4.4A, 
deficiency has been implicated in delayed wound healing, and its expression levels 
correlate with cell invasiveness in numerous cancers154–158.  LIPN has been shown to be 
involved in proper formation of the skin barrier as a 2bp mutation in this gene led to 
ichthyosis159.  AREG is well known for its role in tissue restoration and is an activator of 
transforming growth factor beta160. ACKR3, also known as CXCR7, is involved in 
angiogenesis and cell migration, as well as cancer cell invasiveness161,162.  KRT17 has 
recently been found to be overexpressed in a number of cancers and contributes to tumor 
cell invasiveness163,164.  Its primary role is in wound healing, but it also regulates skin 
inflammation165,166.  CXCR4 is a receptor for CXCL12, which has been shown to recruit 
macrophages to tumor environments and promote M2 phenotypes167.  THBS1 is involved 
in wound healing, the maintenance of homeostasis in the lung, and is an activator of 
latent TGFbeta168–170.  FFAR3 is a short-chain fatty acid receptor and stimulation of this 
receptor results in decreased inflammatory cytokine production by human monocytes171.   
CRISPLD2 has been shown to modulate proliferation of fetal lung fibroblasts and is 
involved in the regulation of extracellular matrix genes during wound healing172.  Of the 





















































































































































Figure 11. Functional characteristics of shared DEGs between LPS + Adenosine and 
LPS+PGE2 relative to LPS stimulation.  Differential expression analysis was performed 
and the list of shared (A) most highly upregulated genes and (B) most highly 
downregulated genes are depicted as the Log2FC relative to LPS stimulation alone. The 
individual Log2FC of each gene for LPS + Adenosine (green bars) and LPS + PGE2 (blue 
bars) stimulations are shown.  The genes colored in purple have roles in growth, 
proliferation and angiogenesis.  The genes colored in red have roles in inflammation.  N=5 
individuals, P-value < 0.05, log2FC > 1. (C) GO term analysis for molecular function was 
performed and the top 5 GO terms are plotted.  Point size indicates # of DEGs in the GO 
term category.  Point color indicates P-value.  Rich factor is the ratio of the # of DEGs per 
# of genes in the GO term category.
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PGE2 versus LPS alone, 13 out of the bottom 20 genes have published roles in 
inflammation (Figure 11B, red). IL12B is an inflammatory cytokine that promotes the 
development of Th1 CD4+ T cells173.  CCL3L3/L1 are sequence variants of the same 
gene (CCL3), which is a chemokine that recruits CCR5 expressing cells174.   CCL8, 
CCL4L2, CCL1, CCL2, and CCL15 are also chemokines, which participate in the 
recruitment of immune cells to sites of inflammation175–177.  CSF2 encodes GM-CSF, 
which can function as a cytokine to promote inflammation178.  TNF is a cytokine that 
mediates inflammation, anti-microbial immunity, and was named after its179 cytotoxicity 
towards tumors.  P2RX7 is a receptor for ATP, which plays a role in the activation of the 
NLRP3 inflammasome180. CMKLR1 encodes the receptor for chemerin, a potent 
macrophage chemoattractant181.  IL27 is a member of the IL-12 family of cytokines and 
promotes expansion and IFNγ production by CD4+ T cells182.  IL1A encodes an 
inflammatory cytokine that can function as an ‘alarmin’ and stimulates the production of 
chemokines183.  Our transcriptomic analysis suggests that the M-CSF macrophage 
response to adenosine and PGE2 during inflammation is highly similar and overlapping.  
Gene ontology (GO) analysis of the list of shared differentially expressed genes by LPS + 
Adenosine and LPS+PGE2 relative to LPS alone, revealed a number of processes that 
were significantly enriched.  These included cytokine activity, chemokine activity, and 
growth factor activity among the top 5 most significantly enriched categories (Figure 
11C).  Using the pathway analysis software, Cytoscape, the differentially expressed genes 
shared by LPS + Adenosine and LPS + PGE2 were separated into 5 predicted network 
clusters based on annotated signaling pathways (Figure 12).  The first cluster includes the 
upregulation of a few growth promoting genes and the downregulation of cytokine genes, 
A.
B.
Figure 12. Functional interaction groups in shared DEGs between LPS + PGE2 and 
LPS + Ado relative to LPS stimulation.  Clusters comprised of  47 and 43 genes (A and 
B, respectively) exhibit functional interactions depicted by edges/arrows.  Genes from the 
shared DEGs in each cluster are depicted by colored circular nodes.  The direction of 
differential expression is depicted by node border color: green  represents upregulated and 
red represents downregulated genes.  White diamond nodes represent predicted regulators. 
(A) Network consisting of genes involved in cytokine signaling and growth factor activity
including TNF, IL1A, THBS1, TGFA and AREG.  Regulators include AP-1 (Jus/Fos),
NFKB1, and EP300. (B) Network consisting of genes involved in tissue repair including





Figure 12 continued.  Clusters comprised of  32, 26 and 35 genes (C, D, E respectively) 
exhibit functional interactions depicted by edges/arrows. (C) Network consisting of genes 
involved in inflammation including IL12B, CSF2, and IL27.  Regulators include STAT1, 
STAT3 and STAT5A. (D) Network consisting of genes involved in chemokine activity 
including CCL1, CCL15, CCL8, CXCL10, CXCL11, CCR7 and CXCR4.  Regulators 
include GNG2 and ARRB1. (E) Network consisting of growth promoting genes including 
VEGFA, CD300E, and PDGFB.  REgulators include MAPK8, FYN and PIK3CA.
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and predicts that NFκB, RelA, and AP-1 (fos, jun), among other transcription factors are 
involved in the regulation of these genes (Figure 12A). The second network consists of 
genes involved in tissue repair including TGFB2 and BMP6 and implicates UBC and 
GSK3B as regulators (Figure 12B).  The third network includes two growth-promoting 
genes of interest, VEGFA and CD300E, and implicates the tyrosine kinases MAPK8 and 
FYN (Figure 12C).  The fourth network predicts that STAT1, STAT3 and STAT5A are 
involved in the regulation of this group of genes including inflammatory CSF2 and 
IL12B (Figure 12D).  The last network includes a number of differentially expressed 
chemokine genes, which are predicted to be regulated by GNG4, GNG2 and ARRB1 
(Figure 12E).  
Single Cell RNA-Sequencing Analysis. Single cell sequencing was performed in order 
to enhance our search for marker genes for regulatory macrophages.  It allowed us to not 
only look for expression levels of genes, similar to bulk RNA-sequencing, but also to 
look at cell numbers expressing select genes.  Lists of the most differentially expressed 
genes by LPS + Adenosine and LPS + PGE2 stimulated cells versus LPS alone as 
determined by single cell sequencing are available in Table II and Table III, respectively.  
From these lists we chose a number of candidate marker genes, mainly encoding cell 
surface or secreted proteins, to examine their expression on a per cell basis for each 
sample, depicted in violin plots, which allowed us to look at the distribution of gene 
expression between cells of each stimulation  (Figure 13) as well as feature plots which 
allowed us to see which specific cells had high and low expression of each gene (Figure 
14).  We hypothesized that some of these genes could serve as potential transcript 
biomarkers for LPS + Adenosine and LPS + PGE2 macrophages, including THBS1, 
Table II. Single cell RNA sequencing markers for LPS + PGE2 versus LPS
Table III. Single cell RNA sequencing markers for LPS + Ado versus LPS
Tables II and III generated with Dr. Ashton Trey Belew
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Figure 13. Violin plots of candidate RNA markers for LPS+Adenosine and 
LPS+PGE2 stimulated M-CSF macrophages. Single cell RNA-seq was performed on 
M-CSF macrophages and differential expression analysis was done between sample
stimulation groups: LPS + Ado (Red), LPS + PGE2 (Green), LPS (Teal), Unstimulated
(Purple).  From this analysis, 9 genes (A) THBS1, (B) VEGFA, (C) CD300E, (D) PLAUR,
(E) OLR1, (F) G0S2, (G) CREM, (H) SAMSN1, and (I) INHBA, were selected based on
their similar expression pattern between LPS + PGE2 and LPS + Adenosine.  These plots





Figure 14. Feature plots of candidate RNA markers for LPS + Adenosine and LPS + 
PGE2 stimulated M-CSF macrophages.  Single cell RNA-seq was performed on M-CSF 
macrophages and differential expression analysis was done between sample stimulation 
groups.  From this analysis, 9 genes (A) THBS1, (B) VEGFA, (C) CD300E, (D) PLAUR, 
(E) OLR1, (F) G0S2, (G) CREM, (H) SAMSN1, and (I) INHBA, were selected based on
their similar expression pattern between LPS + PGE2 and LPS + Adenosine.  These plots 
indicate which cells are expressing these genes relative to one another on a scale of 0-3 















































































































































VEGFA, CD300E, PLAUR, OLR1, G0S2, CREM, SAMSN1 and INHBA. A plot of the 
most variable genes between all 4 samples highlighted a number of genes that we believe 
comprise a part of the M1 macrophage signature, or the response to LPS, because these 
should theoretically be most different from both unstimulated and LPS + Adenosine or 
LPS + PGE2 samples (Figure 15A).  The top 30 genes are labeled and include CXCL10, 
CXCL11, TNF, IL23A, CCL3, CCL4 and a number of other chemokine genes.  The 
genes colored in orange are those that were also found in the top 100 most highly 
upregulated genes by LPS stimulation versus unstimulated in our conventional RNA-
sequencing data.  Conventional RNA-sequencing also demonstrated that the majority of 
the top 25 most highly upregulated genes by LPS relative to unstimulated macrophages 
were significantly downregulated by either adenosine, PGE2 or both (Figure 15B).  This 
suggests that while the transcriptomic changes by adenosine and PGE2 are limited, they 
have important consequences in the host. 
4.3 Discussion 
In this chapter we explored the effects of two molecules, adenosine and PGE2, 
which have previously been shown to modulate the aspects of the inflammatory response 
induced by LPS.  We performed conventional RNA sequencing on macrophages 
stimulated with LPS in the presence of adenosine and PGE2, and found that their 
transcriptional program was highly similar using thorough differential expression 
analysis.  This degree of similarity was observed in the number of shared DEGs between 
the two stimulation conditions.  It was also observed in the direction and extent of the 
changes in gene expression, two parameters that were factored into the Spearman 












































Figure 15.  M1 genes in M-CSF macrophages.  (A) The most significant variable genes 
among all samples (unstimulated, LPS, LPS + Ado and LPS + PGE2) are indicated with red 
dots.  The top 30 most variable genes are labeled.  The genes labeled in orange are also 
found in the top 100 most differentially expressed genes by LPS versus unstimulated in 
bulk RNA-seq analysis. (B) The top 25 most highly upregulated genes by LPS (black) 
versus unstimulated (NS) macrophages and their log2FC are depicted.  The corresponding 
log2FC of LPS + Ado (blue) and LPS + PGE2 (green) versus NS is also depicted. (n=5, * 
indicates genes with a log2FC > 1 and P-value < 0.05 relative to LPS as determined by 
differential expression analysis, error bars represent SEM).
Figure 15A generated with Dr. Ashton Trey Belew



















































adenosine and PGE2 stimulated samples.  We believe that this high degree of similarity 
could be attributed to signaling through g-protein coupled receptors (GPCRs) which leads 
to the intracellular release of cAMP, and downstream activation of transcription factors 
that control numerous genes involved in immune responses.  While similar, PGE2 
appeared to have a more pronounced effect on LPS stimulated macrophages than 
adenosine, due to a higher number of uniquely perturbed transcripts.  However, this could 
be concentration dependent and perhaps it requires more adenosine to achieve even 
further overlap in transcriptomic phenotype with PGE2.  
Pathway analysis, including GO, and careful inspection of individual gene 
changes by LPS + Adenosine and LPS + PGE2 relative to LPS alone led us to conclude 
that these stimuli lead to what our lab refers to as a “regulatory” phenotype.  This 
regulatory phenotype was one characterized by the induction of growth promoting genes 
and the suppression of inflammatory genes.  Single-cell RNA sequencing was performed 
in order to aid in our identification of potential biomarkers for LPS + adenosine and LPS 
+ PGE2 stimulated macrophages.  This technique was powerful because it allowed us to
look at the gene expression patterns of a large number of cells (roughly 4000 cells per 
sample).  It also indicated to us that in vitro stimulation of macrophages is fairly 
homogeneous, since individual samples were stimulated in separate wells, but when all 
the sample data was combined during analysis, the cells clustered together according to 
their stimulation condition.  We identified numerous transcripts that could be used as 
RNA biomarkers to find regulatory macrophages in tissues including THBS1, VEGFA, 
CD300E, PLAUR, OLR1, SAMSN1, and G0S2.  RNA biomarkers also have the 
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potential to be used to scan transcriptomic data generated from different disease or 
immune conditions for the likely presence of regulatory macrophages.   
Single-cell sequencing led us to identify the most variable genes in our data set 
between all stimulations including unstimulated, LPS, LPS + Adenosine and LPS + 
PGE2.  We propose that these genes represented mainly the M1 phenotype, because M1 
genes should be the most changed in the presence of adenosine and PGE2 and relative to 
no stimulation.  This was supported by the fact that 18 out of the 30 most variable genes 
were also present in the top 100 most highly differentially expressed genes by LPS versus 
unstimulated macrophages found by conventional RNA sequencing.  We then 
demonstrated with conventional RNA sequencing that the majority of the top 25 most 
highly upregulated genes by LPS stimulation over resting cells were significantly 
downregulated by combination with adenosine, PGE2, or both.  Many of these genes 
encode inflammatory cytokines and chemokines.  These data imply that while the global 
transcriptomic changes induced by adenosine and PGE2 are relatively limited in number, 
they are highly specific and target some of the most important genes that comprise the 
LPS inflammatory M1 signature.  Overall, the work in this chapter describes two highly 
similar populations of M-CSF macrophages that are characterized by increased 
expression of tissue repair genes and decreased expression of cytokine and chemokine 
genes. 
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5 Comparison of human GM-CSF derived macrophages to M-CSF 
derived macrophages both stimulated with LPS + Adenosine and LPS + 
PGE2 
5.1 Introduction 
While M-CSF is the growth factor constitutively expressed in a number of tissues 
that gives rise to macrophages from infiltrating monocytes, there is a second growth 
factor, GM-CSF, which also leads to differentiated macrophages.  GM-CSF is 
constitutively produced in the lung, but is also induced during inflammatory responses.  
We wanted to know if macrophages differentiated in GM-CSF are equally as capable of 
being programmed into “regulatory” macrophages, as are M-CSF macrophages, in 
response to LPS + Adenosine and LPS + PGE2 stimulation.  This information would be 
useful as GM-CSF could potentially be used to modulate the macrophage activation 
response. 
To explore this question we performed RNA-sequencing on donor matched GM-
CSF derived macrophages stimulated with LPS, LPS + Adenosine, and LPS + PGE2 and 
compared the transcriptomic data to our analysis in the previous chapter for M-CSF 
derived macrophages.  We also did in vitro assays of M-CSF and GM-CSF macrophages 
side by side to further validate the results from our M-CSF RNA-sequencing analysis, 
and to compare the in vitro phenotypes of GM-CSF and M-CSF macrophages.  Before 
we began, we examined the expression of macrophage marker CD68 (Figure 16A), 
dendritic cell marker CD1a (Figure 16B) and macrophage marker CD11b (Figure 16C) to 
confirm that following 7 days of differentiation in M-CSF and GM-CSF, our blood 
monocyte samples did fully mature into macrophages and not dendritic cells. 
5.2 Results 
A. B. C.CD68 CD1a CD11b
M-CSF MΦ M-CSF MΦ
GM-CSF MΦ GM-CSF MΦ
M-CSF Control M-CSF Control





Figure 16.  Flow cytometry validation of M-CSF and GM-CSF derived macrophages. 
Markers for (A) macrophage CD68, (B) dendritic cell CD1a and (C) macrophage CD11b were 
detected on macrophages differentiated in M-CSF and GM-CSF for 7 days to confirm that our 
working cells in both differentiation conditions are in fact mature macrophages.  Relevant isotype 
controls are depicted for each antibody.
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Adenosine and PGE2 sensing in human macrophages. It has recently been published 
that GM-CSF macrophages degrade less ATP in vitro, and produce less adenosine when 
stimulated, compared to M-CSF macrophages184.  We confirmed these results in our M-
CSF and GM-CSF macrophages by examining the kinetics of ATP degradation over a 
period of 2 hours (Figure 17A).  This important finding fits in line with our hypothesis 
that M-CSF macrophages produce more ATP and convert it to adenosine via CD39 and 
CD73, which can subsequently act in an autocrine fashion to suppress macrophage 
inflammation26.  Similarly, at 24 hours post-LPS stimulation, supernatants from M-CSF 
macrophages contained higher levels of PGE2 while the levels of PGE2 in supernatants 
from GM-CSF macrophages were unchanged with LPS stimulation (Figure 17B).   The 
expression of a number of purinergic and prostaglandin receptor genes was measured by 
RT-PCR (Figure 18).  M-CSF macrophages stimulated with LPS upregulated the 
expression of the A2a receptor (Figure 18B), EP2 receptor (Figure 18G) and EP4 
receptor (Figure 18H) while GM-CSF macrophages did not upregulate any of these 
receptors to the same extent, and exhibited lower expression levels for these receptors 
overall.  mRNA expression of the A2b receptor (Figure 18C) did not change with LPS 
stimulation in either M-CSF or GM-CSF, though its expression was higher in M-CSF 
macrophages overall.  The expression of the A1 and A3 receptors decreased following 
LPS stimulation in both M-CSF and GM-CSF macrophages (Figures 18A and 18D, 
respectively).  These two receptors are coupled to the Gi family of signaling proteins, 
which typically decrease cAMP release when activated185.  The mRNA expression of the 
two ecto-enzymes involved in the hydrolysis of ATP, CD39 and CD73, did not change 






























































Figure 17. ATP degradation and PGE2 production by human macrophages. (A) The 
degradation of 20μM ATP was measured over time and expressed per μg of protein per 
sample (n=3 donors,  * P-value < 0.05, ** P-value < 0.01, error bars represent SEM). (B) 
PGE2 was measured in the supernatants of macrophages stimulated with LPS for 24 hours 
(n=10 donors, * P-value < 0.05, lines connect samples from the same individual).
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Figure 18. mRNA expression of purinergic pathway and PGE2 receptor genes in 
M-CSF and GM-CSF macrophages.  Quantitative RT-PCR was used to measure
transcript levels of (A) A1R, (B) A2AR, (C) A2BR, (D) A3R, (E) CD39, (F) CD73, (G)
PTGER2, (H) PTGER4, and (I) PTGER3  following stimulation with LPS for 4 hours (n=5
donors, * P-value < 0.05, ** P-value < 0.01, *** P-value < 0.001, **** P-value < 0.0001,






macrophages (Figures 18E and 18F, respectively.  Lastly, the third receptor for PGE2, 
PTGER3, did not change at the transcript level following LPS stimulation and was 
expressed similarly at low levels in M-CSF and GM-CSF macrophages (Figure 18I). The 
mRNA level of constitutively expressed COX1 did not change with LPS stimulation, nor 
was it different in M-CSF and GM-CSF macrophages (Figure 19A).  However, the 
increase in PGE2 levels in the supernatants of LPS stimulated M-CSF macrophages 
correlated with an increase in the expression of COX2 mRNA, which is inducible (Figure 
19B).  The expression of the prostaglandin synthase gene, MPGES1, seemed to increase 
slightly in LPS stimulated M-CSF macrophages, but this observation was not found to be 
significant (Figure 19C). The expression pattern of adenosine and PGE2 pathway genes in 
M-CSF macrophages was not exclusive to LPS stimulation.  We tested various TLR
ligands including, FSL-1 (TLR2/6), HKLM (TLR2), Loxoribine (TLR 7), and Poly I:C 
(TLR 3).  We noticed that A2AR expression was significantly different between M-CSF 
and GM-CSF macrophages (Figure 20A).  A2BR expression was not significantly 
changed (Figure 20B). mRNA expression for PTGER2 (Figure 20C), PTGER4 (Figure 
20D), MPGES1 (Figure 20E), COX1 (Figure 20F) and COX2 (Figure 20G) was higher in 
M-CSF macrophages than in GM-CSF macrophages for most of the TLR ligands with the
exception of COX1, which was expected.  
Transcriptome comparison of M-CSF and GM-CSF macrophages. Principal 
component analysis (PCA) revealed that M-CSF and GM-CSF macrophages are notably 
different, even following stimulation, and they separated along principal component 1 
(PC1), which explains approximately 54% of the variance among samples (Figure 21).  





















































Figure 19.  mRNA expression of PGE2 synthesis pathway genes.  M-CSF (blue) and 
GM-CSF (grey) macrophages were stimulated with LPS for 4 hours.  (A) COX1, (B) 
COX2 and (C) MPGES1 mRNA levels were measured by RT-PCR (n=7, *** P-value < 




























































































































































































Figure 20.  Purinergic and PGE2 pathway gene expression following stimulation with 
various TLR ligands.  mRNA expression for (A) A2AR, (B) A2BR, (C) PTGER2, (D) 
PTGER4, (E) MPGES1, (F) COX1 and (G) COX2 following 4 hours stimulation with 






























Figure 21.  PCA plot of stimulated human macrophage samples.  M-CSF (squares) and 
GM-CSF (circles) macrophages were stimulated with LPS (orange), LPS + Ado (purple) 
and LPS + PGE2 (pink) for 4 hours and bulk RNA-seq was performed.  Principal 
component analysis (PCA) indicating variance among samples is visualized above.  
Figure generated with Dr. Ashton Trey Belew 
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seen on principal component 2 (PC2), which describes approximately 14% of the 
variance between samples.   Also on PC2, we observed a larger spread between LPS, LPS 
+ Adenosine, and LPS + PGE2 samples, indicating greater variance between M-CSF
samples than we observed in GM-CSF samples.  Volcano plots of all measured 
transcripts indicated that LPS + Adenosine and LPS + PGE2 stimulation of GM-CSF 
macrophages resulted in only 7 and 126 differentially expressed genes (DEGs), 
respectively, compared to LPS alone (Figure 22).  This is significantly lower than the 256 
and 489 DEGs by LPS + Adenosine and LPS + PGE2, respectively, relative to LPS alone 
in M-CSF macrophages. We selected the top 20 differentially expressed genes by M-CSF 
macrophages stimulated with LPS + PGE2 (Figure 23A) and LPS + Adenosine (Figure 
23B) versus LPS alone, and compared their fold changes with the corresponding 
stimulation conditions in GM-CSF macrophages. Many of these transcripts were not as 
highly upregulated in GM-CSF samples.  Similarly, none of the most highly 
downregulated transcripts by LPS + PGE2 (Figure 23C) and LPS + Adenosine (Figure 
23D) versus LPS alone in M-CSF macrophages were as highly downregulated by 
adenosine and PGE2 in GM-CSF macrophages.  The expression of several genes of 
interest, based on their involvement in cell growth and tissue remodeling, was measured 
by RT-PCR in M-CSF and GM-CSF macrophages in order to supplement RNA-
sequencing data.  These genes, including: THBS1, CD93, AREG, VEGFA, CD300E, 
CXCL13, MMP10, and RGS2, were all significantly upregulated by LPS + Adenosine 
and LPS + PGE2 stimulation compared to LPS alone in M-CSF macrophages (Figure 24). 
With the single exception of TGFA, an upregulation of these regulatory transcripts was 
not observed in GM-CSF macrophages (Figure 24).  Altogether, we believe that this 






















































































Figure 22. Volcano plot visualization of DEGs from LPS + Ado and LPS + PGE2 
stimulated macrophages relative to LPS alone.  Bulk RNA-seq of M-CSF (top) and 
GM-CSF (bottom) macrophages stimulated with LPS + PGE2 (left) and LPS + Ado (right) 
was analyzed for differential expression of genes relative to LPS alone.  Green points 
represent significantly changed genes (P-value < 0.05, log2FC > 1).  The numbers of 
significantly upregulated and downregulated genes are indicated in the plot area.  Pink 
points represent genes with a P-value < 0.05 and log2FC < 1. Yellow points represent genes 
with a P-value > 0.05 and log2FC > 1.  Black points represent genes with a P-value > 0.05 




































































































































































































































































































** ** ** **
** * ** * ****** * * *** * *
A. B.
C. D.
Figure 23.  Comparison of expression of DEGs by LPS + Adenosine and LPS + PGE2 
relative to LPS alone in M-CSF and GM-CSF macrophages.  The 20 most upregulated 
differentially expressed genes in M-CSF (blue) (A) LPS + PGE2 and (B) LPS + Ado 
stimulated macrophages relative to LPS alone are listed on the x-axis.  Their 
corresponding fold changes in GM-CSF (grey) LPS+ PGE2 and LPS + Adenosine 
macrophages relative to LPS are plotted (n=5, *P-value < 0.05, ** P-value < 0.01, *** 
P-value < 0.001).  The 20 most downregulated differentially expressed genes in M-CSF
(C) LPS + PGE2 and (D) LPS+Adenosine stimulated macrophages relative to LPS alone
are listed on the x-axis.  Their corresponding fold changes in GM-CSF LPS + PGE2 and
LPS + Ado macrophages relative to LPS are plotted (n=5, *P-value < 0.05, ** P-value <
0.01, *** P-value < 0.001).
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Figure 24.  mRNA expression of genes of interest in M-CSF and GM-CSF 
macrophages.  Macrophages were stimulated with LPS, LPS + Adenosine and LPS + 
PGE2 for 4 hours and the expression for genes THBS1, CD93, AREG, VEGFA, CD300E, 
CXCL13, MMP10, RGS2, and TGFA was measured by RT-PCR (n=5, * P-value < 0.05, 




transcriptomic data indicates a defect in adenosine and PGE2 sensing by GM-CSF 
macrophages.  We hypothesize that this lack of sensing contributes to GM-CSF 
macrophages being hyper-inflammatory. 
Functional assays of human macrophages.   Human umbilical vein endothelial 
(HUVEC) cells cultured in conditioned media for 24 hours from stimulated M-CSF and 
GM-CSF macrophages exhibited tube formation on a Matrigel surface (Figure 25A).  
HUVEC cells cultured in conditioned media from M-CSF macrophages stimulated with 
LPS + Adenosine and LPS + PGE2 exhibited the highest levels of tube formation based 
on tube length (Figure 25B) and the number of nodes between tubes (Figure 25C).  
HUVEC cells cultured in conditioned media from GM-CSF macrophages stimulated with 
LPS + Adenosine and LPS + PGE2 showed no increase in tube formation relative to 
HUVECs cultured in supernatants of LPS stimulated macrophages.  In fact, HUVEC cells 
cultured in media from stimulated GM-CSF macrophages exhibited defects in tube 
formation relative to those grown in media from unstimulated GM-CSF macrophages and 
relative to those grown in media from M-CSF macrophages.  
One of the transcripts that emerged from both our bulk RNA-sequencing and 
single cell RNA-sequencing analysis as being highly differentially expressed in LPS + 
Adenosine and LPS + PGE2 stimulated M-CSF macrophages relative to LPS alone was 
CD300E.  CD300E was expressed on the surface of a higher percentage of cells in LPS+ 
Adenosine and LPS + PGE2 stimulated M-CSF macrophages compared to LPS 
stimulated M-CSF macrophages (Figure 26A).  The level of CD300E expression (median 
fluorescence intensity) was also increased with LPS + Adenosine and LPS + PGE2 



































































Figure 25.  HUVEC cell tube formation in the presence of macrophage conditioned 
media.  Human monocytes were cultured in M-CSF or GM-CSF for 7 days then left 
unstimulated or stimulated with LPS, LPS + Ado and LPS + PGE2 for 24 hours at which 
point supernatants were collected for further studies. (A) HUVEC cell tube formation was 
observed after 24 hour exposure to supernatants harvested from stimulated M-CSF and 
GM-CSF macrophages from one representative donor (n=3 donors total).  Representative 
images were captured by brightfield microscopy with “find edges” contrast applied in 
ImageJ in order to be able to see the tubes. (B) Total tube length was measured in pixels 
manually using ImageJ software on various images of HUVEC cells exposed to 
supernatants of macrophages from multiple donors (n=3 donors, ** P-value ˂0.01, **** 
P-value <0.0001 between M-CSF and corresponding GM-CSF samples; # P-value <0.05,
## P-value <0.01 for M-CSF samples relative to NS supernatants; error bars represent
SEM). (C) The number of nodes, defined as 3 or more tubes originating from one point,
was counted manually using ImageJ software on various images of HUVEC cells exposed
to supernatants of macrophages from multiple donors (n=3 donors, ** P-value ˂0.01, ****
P-value <0.0001 between M-CSF and corresponding GM-CSF samples; # P-value <0.05,
## P-value <0.01 for M-CSF samples relative to NS supernatants; error bars represent
SEM).
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Figure 26.  Flow cytometry of CD300E surface expression.  Macrophages were 
untreated or stimulated with LPS, LPS + Ado and LPS + PGE2 for 24 hours.  (A) Dot plots 
of CD300E expression from 1 representative donor are shown and gates indicate the 
percentage of cells that are CD300E+ and CD300E-.  (B) Median fluorescence intensity of 
CD300E levels on stimulated macrophages was calculated (n=5, ** P-value < 0.01 versus 
LPS stimulated samples alone; # P-value < 0.05, ## P-value < 0.01 between M-CSF and 





in stimulated GM-CSF macrophages (Figure 26B).  This lead us to conclude that 
CD300E is a suitable biomarker unique to M-CSF macrophages stimulated with LPS + 
Adenosine and LPS + PGE2.  PLAUR was another one of the transcripts that was highly 
differentially expressed in our single cell RNA-sequencing analysis.  We measured the 
surface expression of PLAUR by flow cytometry and found that its expression was 
indeed increased by LPS + Adenosine and LPS + PGE2 stimulation in M-CSF 
macrophages (Figure 27).  We believe that PLAUR could be used in combination with 
CD300E as a secondary marker for these regulatory cells; however, it is also expressed in 
GM-CSF macrophages so it would not be a suitable marker to use on its own.  We also 
looked at the levels of secreted, soluble proteins from M-CSF and GM-CSF 
macrophages.  Thrombospondin-1 (Figure 28A) and VEGFα (Figure 28B), both growth-
promoting proteins, were secreted at higher levels by M-CSF macrophages than by GM-
CSF macrophages.  The cytokine IL-6 was significantly decreased with adenosine and 
PGE2 stimulation in M-CSF macrophages but not in GM-CSF macrophages (Figure 
28C).  To our surprise, anti-inflammatory IL-10 levels were not increased by adenosine 
and PGE2 in M-CSF cells, and were actually decreased by PGE2, which is contrary to the 
behavior of mouse macrophages (Figure 28D).  However, the levels of IL-10 were 
significantly higher in M-CSF macrophages than in GM-CSF macrophages.  Preliminary 
data indicated that stimulation of M-CSF macrophages with LPS in combination with a 
cell permeable cAMP analog specific for protein kinase A (PKA) activation led to 
increased levels of both THBS1 and VEGFα (Figure 28E).  However, stimulation with a 
cell permeable cAMP analog specific for exchange protein activated by cAMP (Epac) did 


























































Figure 27.  Flow cytometry of PLAUR surface expression.  Macrophages were 
untreated or stimulated with LPS, LPS + Ado and LPS + PGE2 for 8 hours.  The median 
fluorescence intensity of PLAUR levels on stimulated macrophages was calculated (n=3, 






































































































































































































Figure 28.  Growth promoting, anti-inflammatory cytokine secretion by M-CSF and 
GM-CSF macrophages.  Macrophages were differentiated for 7 days in M-CSF or 
GM-CSF and then stimulated with LPS, LPS + Adenosine, and LPS + PGE2 for 24 hours. 
(A) THBS1, (B) VEGFa, (C) IL-6 and (D) IL-10 levels were measured in the supernatants
by ELISA (n=4-7; * P-value < 0.05, ** P-value < 0.01 relative to LPS stimulation alone; #
P-value < 0.05, ## P-value < 0.01, ### P-value < 0.001 between M-CSF and GM-CSF
samples; error bars represent SEM; points are color coded by donor).  (E) Preliminary data
depicting THBS1 and VEGFa levels in macrophages stimulated with LPS coupled to cell
permeable Epac selective (8-pCPT-2-O-Me-cAMP-AM) cAMP analog  or PKA selective

























































The levels of inflammatory cytokines TNF (Figure 29A), IL-12p40 (Figure 29B) 
and GM-CSF (Figure 29C) were higher in supernatants collected from stimulated GM-
CSF derived macrophages than in supernatants from M-CSF macrophages.  IL-12p40 and 
GM-CSF levels were unchanged by LPS + Adenosine and LPS + PGE2 relative to LPS 
stimulation alone in GM-CSF derived macrophages, indicating a resistance of these 
macrophages to regulatory stimuli.  To further explore the extent of GM-CSF resistance 
to adenosine and PGE2, we use IL-12p40 production as a readout in response to 
increasing concentrations of adenosine and PGE2 coupled to LPS stimulation (Figure 30).  
M-CSF macrophages responded with a dose dependent decrease in IL-12p40 production
with a significant decrease with just 25 µM of adenosine and 1 nM of PGE2, while GM-
CSF macrophages did not have a significant decrease in IL-12p40 production in the 
presence of concentrations as high as 50 µM adenosine and 50 nM PGE2. 
Kinetics and modulation of cytokine production.  We sought to gain insight regarding 
the kinetics of responses for both M-CSF and GM-CSF macrophages in response to LPS 
stimulation and also to examine the effects of different priming conditions on cytokine 
production.  First we investigated endotoxin tolerance, a mechanism by which innate 
immune cells limit their inflammation186–188.  We demonstrated that LPS priming of M-
CSF and GM-CSF macrophages both led to the tolerance of a second LPS exposure in 
terms of TNF production and that there was no difference in tolerance between the two 
populations of macrophages (Figure 31A).  Next, we examined whether GM-CSF 
priming had any effect on the cytokine production of M-CSF macrophages.  Priming M-
CSF derived macrophages with GM-CSF led to an increase in TNF (Figure 31B) and IL-



































































































































Figure 29.  Inflammatory cytokine secretion by M-CSF and GM-CSF  macrophages.  
Macrophages were differentiated for 7 days in M-CSF or GM-CSF and then stimulated 
with LPS, LPS + Adenosine, and LPS + PGE2 for 24 hours.  (A) TNF, (B) IL-12p40 and 
(C) GM-CSF levels were measured in the supernatants by ELISA (n=5-9, * P-value < 0.05
relative to LPS stimulation alone; # P-value < 0.05, ## P-value < 0.01 between M-CSF and






















































































































































Figure 30.  Modulation of macrophage IL-12p40 secretion by increasing 
concentrations of adenosine and PGE2.  M-CSF (blue) and GM-CSF (black) 
macrophages were stimulated with LPS coupled with various concentrations of adenosine 
and PGE2, indicated on the x-axis, for 24 hours and IL-12p40 levels were measured in the 
supernatants by ELISA (n=5 M-CSF, n=4 GM-CSF, * P-value < 0.05, *** P-value < 0.001, 


























































































































































































Figure 31.  Priming in M-CSF and GM-CSF macrophages.  (A) M-CSF (blue) and 
GM-CSF (grey) macrophages were unprimed or primed for 24 hours with LPS followed by 
a wash and subsequent LPS stimulation for an additional 24 hours.  Supernatants were 
collected and assayed for TNF levels by ELISA (n=3, * P-value < 0.05, error bars represent 
SEM).  Macrophages were grown for 7 days in M-CSF and then unprimed (black) or 
primed with GM-CSF for different lengths of time as indicated on the x-axis (purple) or 
grown in GM-CSF alone for 7 days (grey).  Following a wash, macrophages were 
stimulated with LPS for 24 hours and supernatants were collected to assay for (B) TNF, (C) 
IL-12p40 and (D) IL-10 by ELISA (n=3, * P-value < 0.05, ** P-value < 0.01, **** P-value 
< 0.0001 relative to M-CSF LPS stimulation alone, error bars represent SEM).
82
83	
the levels of TNF and IL-12p40 in GM-CSF primed macrophages were not as high as in 
macrophages that were derived in GM-CSF alone for 7 days.  IL-10 production by M-
CSF macrophages was not affected by various lengths of GM-CSF priming time (Figure 
31D).  Altogether, this data indicates that although GM-CSF is able to alter the M-CSF 
macrophage response, it is most effective at macrophage polarization when present as a 
growth factor during the monocyte to macrophage differentiation process.  We next 
observed that TNF production was sustained longer in LPS stimulated GM-CSF 
macrophages compared to M-CSF macrophages following removal of the LPS stimulus 
(Figure 32A).  Additionally, the accumulated levels of TNF (Figure 32B) and IL-12p40 
(Figure 32C) were higher over the collected timepoints in LPS stimulated GM-CSF 
macrophages compared with M-CSF macrophages. In order to examine the role of 
endogenously produced adenosine and PGE2 during inflammatory contexts, we made use 
of pharmacological inhibitors of adenosine and PGE2 receptors.  Preliminary data 
suggested that simultaneous pharmacological blockade of the A2A receptor, EP2 receptor 
and EP4 receptor appeared to prevent the upregulation of transcript levels of three growth 
promoting and candidate marker genes for regulatory macrophages, CD300E (Figure 
33A), VEGFA (Figure 33B) and THBS1 (Figure 33C) at later (12 hour) but not earlier (4 
hour) time points.  Pharmacological blockade of the even the EP4 receptor alone led to a 
significant increase in inflammatory TNF levels in LPS stimulated M-CSF macrophage 
supernatants after 24 hours (Figure 33D).  Conversely, the EP4 antagonist had virtually 
no effect on LPS stimulated GM-CSF macrophages. This suggests that M-CSF 
macrophages are sensitive to endogenously produced PGE2 in their environment, but 
GM-CSF macrophages are not. 
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Figure 32.  Kinetics of inflammatory TNF and IL-12p40 cytokine secretion by M-CSF 
and GM-CSF macrophages.  (A) Human macrophages were stimulated for 2 hours with 
LPS and supernatants were collected and assayed for TNF levels by ELISA.  Macrophages 
were washed and media was replaced at each timepoint following supernatant collection 
(n=7, ** P-value < 0.01, **** P-value < 0.0001, error bars represent SEM).  The 
accumulation of (B) TNF and (C) IL-12p40 was measured by ELISA over a period of 24 











































































































































Figure 33.  Pharmacological inhibition of adenosine and PGE2 receptors.  M-CSF 
macrophages were stimulated with LPS, and LPS + a cocktail of small molecule 
antagonists (against A2a, A2b, EP2, and EP4 receptors) for 4 and 12 hours. (A) CD300E, 
(B) VEGFA and (C) THBS1 mRNA was measured (n=4, error bars represent SEM).  (D)
M-CSF and GM-CSF macrophages were stimulated with LPS and LPS + ONO AE3 208
5nm (an EP4 receptor antagonist) for 24 hours and TNF levels in the supernatants were
measured by ELISA (n=7, * P-value < 0.05 relative to LPS stimulation alone; ####




In this chapter, we elaborated on the findings pertaining to the human M-CSF 
macrophages described in chapter 4.  We also made side-by-side comparisons of M-CSF 
and GM-CSF macrophages in order to explore whether these two growth factors lead to 
macrophages that adopt similar phenotypes upon stimulation.  It is common to use either 
M-CSF or GM-CSF to generate monocyte-derived macrophages for further study.
However, the combination of GM-CSF with IL-4 is used to obtain monocyte derived 
dendritic cells189, which may lead to questioning of whether our differentiation protocol 
resulted in mature macrophage populations.  The expression of CD68 and CD11b on both 
M-CSF and GM-CSF derived cells and the lack of expression of CD1a led us to believe
that our working cells were in fact macrophages. This is in line with results from other 
labs190,191.   
We demonstrated that M-CSF and GM-CSF macrophages differed with respect to 
the purinergic and prostaglandin E2 pathways.  We hypothesized that M-CSF 
macrophages may produce more ATP upon TLR stimulation than GM-CSF 
macrophages, but ATP secretion is difficult to measure due to its rapid conversion to 
adenosine by enzymes on the macrophage surface.  Therefore, we measured the 
degradation of high concentrations of exogenously added ATP by M-CSF and GM-CSF 
macrophages to find that M-CSF macrophages degraded higher levels of ATP over the 
chosen timepoints.  This supported similar results found by another group who 
demonstrated that M-CSF macrophages degraded more ATP than GM-CSF macrophages 
in 30 minutes regardless of stimulation condition184.  Increased ATP degradation suggests 
that there is more endogenous, immunosuppressive adenosine available adjacent to the 
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macrophage surface to signal through the adenosine receptors to promote a transition to a 
regulatory phenotype.  We also demonstrated that LPS stimulated M-CSF macrophages 
secrete more PGE2, which we believe can act in an autocrine fashion in order to promote 
the transition to a regulatory phenotype in M-CSF but to a lesser extent in GM-CSF 
macrophages.  This was further supported by mRNA expression of COX2, which was 
significantly induced in LPS stimulated M-CSF macrophages but not in GM-CSF 
macrophages.  Not only were these molecules produced at lower levels in GM-CSF 
macrophages, but the receptors for sensing them, A2a receptor, A2b receptor, EP2 
receptor and EP4 receptor, were also transcribed at significantly lower levels following 
TLR stimulation by LPS and various other TLR ligands.  Notably, these 4 receptors 
mediate the immunosuppressive effects of adenosine and PGE256,192,193.   This also 
suggests that the differential regulation of the purinergic and PGE2 pathway genes by M-
CSF and GM-CSF macrophages is consistent in different contexts of pathogenic 
infection.  
Transcriptomic data allowed us to compare global genetic changes between 
stimulated M-CSF and GM-CSF macrophages.  The PCA analysis alone indicated to us 
that M-CSF and GM-CSF macrophages are transcriptionally different even under similar 
stimulation conditions.  Stimulation with LPS, LPS + Adenosine, and LPS + PGE2 
exhibited more variance among samples in M-CSF than in GM-CSF macrophages 
suggesting that GM-CSF macrophages are less susceptible to phenotypic modulation by 
adenosine and PGE2.  This was further supported by the number of DEGs by LPS + 
Adenosine and LPS + PGE2 relative to LPS alone, which was significantly higher in M-
CSF macrophages than GM-CSF macrophages.  Many of the upregulated and 
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downregulated genes by LPS + Adenosine and LPS + PGE2 relative to LPS alone in M-
CSF macrophages were not up- or downregulated to the same extent in GM-CSF 
macrophages subject to the same conditions.  Many of these upregulated genes had 
growth promoting functions, demonstrating that GM-CSF macrophages are not easily 
programmed to promote tissue repair.  This was highlighted by the fact that M-CSF 
macrophages stimulated with adenosine and PGE2 secreted factors that promoted tube 
formation by HUVEC cells, while stimulated GM-CSF macrophages secreted factors the 
inhibited tube formation.  Tube formation has been proposed to be a reliable in vitro 
assay for angiogenesis as it involves adhesion, migration and tubule formation all in one 
experiment194. 
Surface proteins CD300E and PLAUR were found to have increased expression 
on adenosine and PGE2 stimulated macrophages.  CD300E in particular was not 
expressed above baseline on GM-CSF macrophages, making it a more suitable biomarker 
for M-CSF regulatory macrophages.  Secreted proteins THBS1 and VEGFα were also 
higher in adenosine and PGE2 stimulated M-CSF macrophages, suggesting that they 
could also be used as biomarkers for M-CSF regulatory macrophages.  Both of these 
proteins are well known contributors to the wound healing process195,168.  On the other 
hand, levels of inflammatory cytokines, TNF, IL-12p40 and GM-CSF were secreted at 
higher levels in LPS stimulated GM-CSF macrophages, and the addition of adenosine 
and PGE2 did not dampen their secretion.  This implies that GM-CSF macrophages are 
programmed to resist phenotypic change in response to resolving molecules in the 
inflammatory milieu in order to maintain higher levels of activation.  Because 
macrophages are highly plastic in nature, we wanted to know if adding GM-CSF to M-
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CSF differentiated macrophages could skew their phenotype.  This had previously been 
shown to be true by another group who demonstrated that the M-CSF and GM-CSF 
differentiation of macrophages was not end stage, and that a subsequent period of 6 days 
in the opposite growth factor could reverse original phenotypes196.  We demonstrated that 
this was the case for the secretion of inflammatory cytokines TNF and IL-12p40, and the 
extent of skewing correlated with the length of GM-CSF priming time.  However, GM-
CSF priming did not negatively affect the levels of IL-10 secretion.  Additionally, GM-
CSF priming did not restore TNF and IL-12p40 levels to the levels seen in GM-CSF 
differentiated macrophages.  Therefore, it appears that exposure longer than 24 hours to 
GM-CSF is most effective in programming macrophages to reach a more inflammatory 
potential.   
While total amounts of inflammatory cytokine secretion contribute to 
immunopathology, the duration of cytokine secretion also has an important role in 
immune responses.  GM-CSF macrophages secreted TNF at higher levels than M-CSF 
macrophages for up to 18 hours following the removal of stimulus.  GM-CSF 
macrophages also had significantly higher steady state levels of TNF and IL-12p40 in 
their supernatants at different time points up to 24 hours.  Together these data suggest 
that M-CSF macrophages terminate their activation more effectively and faster than their 
GM-CSF counterparts and transition to a resolving phenotype.  The expression of marker 
gene candidates CD300E, VEGFA and THBS1 were measured at early (4 hour) and later 
(12 hour) time points following LPS stimulation in the presence of pharmacological 
inhibitors of the A2ar, EP2 and EP4 receptors.  This preliminary data suggested to us that 
pharmacological blockade of these receptors may prevent the upregulation of these 
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transcripts at later time points, but may not have an effect on the upregulation of these 
transcripts at early time points.  We hypothesize that this may be due to the fact that the 
ligands for these receptors need some time to be produced endogenously in order for 
them to act in an autocrine manner.  The pharmacological blockade of the EP4 receptor 
alone led to more than double an increase in TNF production by M-CSF macrophages in 
response to LPS, suggesting that under normal conditions, endogenous PGE2 helps to 
limit inflammatory TNF.  The pharmacological blockade of the EP4 receptor had no 
effect on the high levels of TNF produced by GM-CSF macrophages, which is not 
surprising, due to the presumed lack of EP4 receptor expression by GM-CSF 
macrophages based on mRNA data. 
Overall, the data in this chapter combined with the data in chapter 4 led us to 
propose a model for both the regulation of M-CSF macrophage activation and the lack of 
regulation in GM-CSF macrophages (Figure 34).  We hypothesize that M-CSF 
macrophages are better equipped to turn off inflammation and initiate a program of tissue 
repair due to the production and increased sensitivity to the resolving molecules, 
adenosine and PGE2.  We demonstrate that a number of components proposed in our 
model were lacking or present at lower levels in GM-CSF macrophages, which we 
believe helps to explain why GM-CSF macrophages are known to be hyper-
inflammatory.  In M-CSF but not GM-CSF macrophages, the expression of A2ar, A2br, 
EP2 and EP4 receptors is upregulated following TLR stimulation, making them more 
ready to sense adenosine and PGE2 in their environment.  The degradation of ATP and 
production of PGE2 by GM-CSF macrophages is also lower than in M-CSF macrophages.  








Figure 34.  Proposed pathway for endogenous regulation of M-CSF macrophage 
activation and lack of regulation of GM-CSF macrophages.  TLR activation by PAMPs 
leads to the transcription and production of inflammatory mediators including the 
cytokines and chemokines.  However, TLR activation also leads to the production of ATP 
which is degraded to adenosine.  Adenosine signals through A2aR and A2bR to inhibit 
inflammation and initiate production of growth promoting proteins.  Similarly, TLR 
activation leads to the production of PGE2,via COX and MPGES proteins, which then 
signals through EP2 and EP4 receptors to inhibit inflammation and initiate production of 
growth promoting proteins.  We propose that these two molecules contribute to the 
resolution and control of M-CSF macrophage activation in response to pathogens. 
Components marked with a red (X) are those that are inhibited in macrophages 
differentiated in GM-CSF.  Therefore, we propose that GM-CSF macrophages are unable 

































M-CSF and GM-CSF macrophages, are contributing factors to the propensity of these
cells to either perpetuate inflammation or promote tissue repair. 
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6 Conclusions and Future Directions 
Macrophages are highly responsive to their tissue environments. In this research, 
we explore the effects of a number of different stimuli that macrophages may encounter 
in the host under different contexts.  We demonstrate that Type I and Type II IFNs 
modulate the expression of adenosine receptors in mouse macrophages. We have also 
characterized a population of human M-CSF macrophages with growth promoting and 
pro-angiogenic activity that we believe arises following the termination of every immune 
response as a mechanism to restore tissue homeostasis. We demonstrate that GM-CSF 
human macrophages exhibit prolonged inflammatory responses because they are 
defective in this transition. These observations have several potential implications for 
influencing immunity and inflammatory responses.  First, they predict that IFN 
inflammatory responses are partially regulated in macrophages by the purinergic system.  
Second, they suggest that M-CSF macrophages are poised to promote tissue repair and 
that a lack of this growth factor has the potential to lead to chronic inflammatory 
conditions.  Third, they suggest that GM-CSF may prolong immunity and delay immune 
resolution not only by increasing inflammation but also by delaying its resolution and 
preventing the upregulation of genes critical for tissue repair.  The failure of GM-CSF 
macrophages to transition to a growth-promoting phenotype could explain the mechanism 
of action of this protein in disease.  Tissue GM-CSF levels are elevated in numerous 
autoimmune/inflammatory conditions including multiple sclerosis197, rheumatoid 
arthritis198, systemic inflammation112, and allergic responses113.  A multitude of clinical 
trials for monoclonal antibodies to GM-CSF have been undertaken in the context of these 
diseases102,199. 
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Exploring macrophage activation on a spectrum by examining responses to 
molecules aside from the usual M1 and M2 stimuli, furthers our understanding of 
macrophage function in numerous physiological and disease environments.  For example, 
our results are relevant in the context of certain cancers, as adenosine and PGE2 are 
present at high levels in the tumor microenvironment, known to harbor numerous tumor 
associated macrophages47,57,200–202.  Because macrophages are highly sensitive to small 
changes in their surroundings, it is important to continue to investigate macrophage 
responses to a wide range and combination of stimuli.   
The findings presented in this work illuminate the similarity of the macrophage 
response to adenosine and PGE2 during inflammation.  We believe that this could be 
attributed to the signaling of these molecules through g-protein coupled receptors 
(GPCRs) and downstream cAMP production.  It is possible that this macrophage 
phenotype extends to stimulation with numerous other GPCR ligands, which should be 
further explored.   GPCRs make up the largest class of receptors for approved membrane 
drug targets203.  Therefore, it is possible that there are existing drugs that can be used in 
contexts that we have not yet discovered. 
Much of the research on human monocyte-derived macrophages is highly variable 
as different labs have multitudes of protocols for generating macrophages from 
monocytes.  This work shows that using GM-CSF alone as a differentiation factor can 
skew or bias the resulting macrophages to be inflammatory and resistant to the transition 
to a growth promoting phenotype.  We propose that M-CSF is the growth factor most 
“neutral” to generate human macrophages. 
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Our observation that stimulated GM-CSF macrophages are resistant to the anti-
inflammatory effects of adenosine and PGE2 illuminates the potential use of GM-CSF in 
contexts in which it would be beneficial for macrophages to be hyper-inflammatory.  One 
example would be the use of GM-CSF as a vaccine adjuvant.  There are recent clinical 
trials testing GM-CSF as an adjuvant in cancer vaccines due to its anti-tumor 
properties204,205.  GM-CSF could also potentially be used in parasitic diseases such as 
leishmaniasis in which cell mediated immune responses are needed for pathogen 
killing130. In fact, topical application of GM-CSF to lesions has been demonstrated to 
reduce the healing time in cutaneous leishmaniasis patients, due to increased parasite 
killing206.  
We identified promising protein biomarkers for regulatory macrophages 
including, THBS1, VEGFA, CD300E and PLAUR which could potentially be used in 
combination with cell specific markers such as CD68 and CD11b to identify growth 
promoting macrophages in histological samples or in vivo.  Exploring where these 
macrophages are located in the host can help us better understand their functional roles 
and allow us to target them in different diseases.  Along with this, another potential use 
for these biomarkers is during therapeutic testing in order to determine if certain drugs 
are effective in producing the intended phenotype in macrophages.  
This work raises new questions that would benefit from further research. Pathway 
analysis led to the prediction of many transcriptional regulators of the genes modulated 
by regulatory macrophages.  It would be beneficial to identify specific transcriptional 
regulators using pharmacological tools or protein interaction studies.  This way, 
regulatory macrophage phenotypes could be mimicked with the modulation of a few key 
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proteins.  Additionally, further exploration of the mechanism of M-CSF and GM-CSF 
control of the purinergic and PGE2 pathways is needed, including how the expression of 
the receptors for these molecules is regulated.  We highlighted the pro-angiogenic nature 
of LPS + Adenosine and LPS + PGE2 macrophages, which has implications for 
macrophage actions in the tumor microenvironment as well as in wound healing or tissue 
repair.  It would be interesting to compare the transcriptomic data generated in this work 
with transcriptomic data generated by other researchers on macrophages in known 
disease environments.  This could help us to determine whether regulatory macrophages 
are participating in specific disease situations.  Additionally, it would be useful to 
compare the transcriptomic data in this research to datasets from primary human tissue-
resident macrophages, such as alveolar macrophages from the lung in order to explore the 
similarity of the macrophages we studied, to those in different tissues. Ultimately, the 
hope is that any of the molecular pathways discussed in this work could be targeted to 
ameliorate different disease pathologies. 
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